case_id,mode,case_type,iteration,Q0_answer,Q0_reasoning,Q1_answer,Q1_reasoning,Q2_answer,Q2_reasoning,Q3_answer,Q3_reasoning,Q4_answer,Q4_reasoning,Q5_answer,Q5_reasoning,Q6_answer,Q6_reasoning,Q7_answer,Q7_reasoning,Q8_answer,Q8_reasoning,input_tokens,output_tokens,total_tokens
Case3223,baseline,without_policy,iter1,BRCA1/2,The referral explicitly requests BRCA1 and BRCA2 testing.,Not Specified,BCBS_FEP BRCA coverage is based on personal/family cancer history rather than strict patient age limits; no age-based exclusion is documented for BRCA testing in this clinical context.,Not Specified,BCBS_FEP policy does not restrict BRCA ordering to a specific provider specialty in typical practice; the record shows referral by a general practitioner which is acceptable and no specialty requirement is documented.,Yes,"BCBS_FEP criteria consider a first‑degree relative with epithelial ovarian cancer an accepted indication for BRCA1/2 testing; the patient’s sister had epithelial ovarian cancer, satisfying medical indication.",Not Specified,"There are no BCBS_FEP prior‑test requirements (e.g., other genetic tests) that must be completed before germline BRCA1/2 sequencing in this scenario; the prior CMA for a congenital heart defect is unrelated and not required for BRCA testing.",Yes,"Family history criteria are relevant and met: the patient has a first‑degree relative (sister) with epithelial ovarian cancer, which is specified in coverage criteria for BRCA testing.",No,"BCBS_FEP expects documentation of pre‑test genetic counseling/informed consent for hereditary cancer testing; the chart notes no documentation of pre‑test genetic counseling, so the counseling requirement is not met.",81228,"The requested test is germline BRCA1/2 sequencing; among the provided CPT options, 81228 corresponds to BRCA gene sequencing (best match for BRCA1/2 testing).",No,"Although the patient meets medical indication (first‑degree relative with ovarian cancer) and age is not a barrier, coverage requirements by BCBS_FEP include documentation of pre‑test genetic counseling; because counseling is not documented, the test is not covered as presented.",1963,2029,3992
Case14226,baseline,without_policy,iter1,BRCA1/2,Patient is being evaluated specifically for germline BRCA1 and BRCA2 testing per the clinical note; request explicitly names BRCA1/2.,Not Specified,Cigna's BRCA coverage criteria are generally driven by personal/family cancer history and calculated mutation probability rather than a strict age cutoff; no age-based exclusion is specified that would bar testing for a 55-year-old.,Not Specified,"Cigna typically requires an order from a licensed provider but does not restrict BRCA testing to a single named specialty in most indications; the record shows oncology is ordering the test, which is an appropriate ordering provider type and no payer-specific specialty restriction is documented in the provided information.",No,"Cigna's BRCA policy defines specific medical indications (personal history of BRCA-associated cancers or meeting calculator probability thresholds). The patient has a personal history of an unspecified primary solid tumor (not documented as a BRCA-associated cancer) and a calculated BRCA probability of 2.5%, which is below Cigna's commonly applied calculator threshold for testing (policy threshold = 3%); therefore the patient does not meet a defined clinical indication.",Not Specified,Cigna's BRCA germline testing policy does not universally mandate completion of prior genetic tests before ordering germline BRCA testing (prior tumor testing or other genetic tests are situational); the provided information does not document any payer-required prior testing for this scenario.,No,"Cigna's BRCA criteria consider family history of breast, ovarian, pancreatic, or prostate cancer as relevant. The family history here notes only a mother with a severe hematologic/immunologic disorder, which is not a BRCA-related cancer history and thus does not meet family-history-based criteria.",No,"Cigna's BRCA policy generally requires documentation of pre-test genetic counseling by a qualified genetics professional prior to germline BRCA testing; the record explicitly states no pre-test genetic counseling was completed, so counseling requirements are not met.",Not Specified,"The clinical request is for BRCA1/2 single-gene germline testing. The specific BRCA CPT codes (e.g., single-gene BRCA codes) are not among the listed options with clear mapping, and the provided options include codes for other test types (81415 = whole exome) — therefore the best answer from the supplied choices is Not Specified.",No,"Under Cigna BRCA coverage criteria, the patient does not meet medical indication (calculator probability 2.5% below the typical 3% threshold and tumor type not documented as BRCA-associated) and pre-test genetic counseling—required by policy—was not completed. Based on these payer-specific coverage requirements, the test is not covered.",2026,2456,4482
Case10451,baseline,without_policy,iter1,WES,The clinical note explicitly states the patient was referred for whole exome sequencing (WES) by neurology to evaluate an unexplained neurodevelopmental disorder.,Not Specified,UHC WES coverage criteria are indication-driven (unexplained moderate–severe intellectual disability/GDD) and do not impose a firm age cutoff in policy language; the patient is pediatric (10 years) and age is not a disqualifying factor.,Not Specified,UHC policies require an appropriate ordering clinician but typically do not restrict ordering to a single specialty; the order is from neurology (an appropriate specialist) and policy does not mandate only geneticists/genetic counselors as orderers.,Yes,"Coverage criteria specify WES for unexplained moderate to severe intellectual disability/neurodevelopmental disorder; the patient has childhood-onset moderate–severe intellectual disability and an unexplained neurodevelopmental presentation, meeting the medical indication.",Yes,"UHC requires prior standard testing such as chromosomal microarray (CMA) before WES for developmental disorders; the record states CMA was performed and nondiagnostic, satisfying the prior test requirement.",No,"While family history of similar neurodevelopmental phenotypes can support testing, the documented family history is a sibling with a brief resolved unexplained event (BRUE-like) rather than a similar intellectual disability phenotype; this does not meet family-history-based eligibility criteria.",Not Specified,"UHC policies recommend pre- and post-test genetic counseling but do not universally require documented genetic counseling as an absolute condition for coverage of diagnostic WES; here there is no documentation, but policy does not explicitly deny coverage solely for absence of documented counseling.",81415,"The requested test is whole exome sequencing (proband-level clinical exome), which corresponds to CPT code 81415 under current molecular/genetic CPT coding for clinical exome sequencing.",Yes,"From a UHC coverage-adjudication perspective the patient meets the clinical indication (unexplained moderate–severe intellectual disability), has required prior CMA testing documented as nondiagnostic, and the order is placed by an appropriate specialist (neurology); therefore WES is covered.",1999,1890,3889
Case4196,baseline,without_policy,iter1,WES,The clinical note explicitly states whole exome sequencing (WES) is being requested as the next diagnostic step.,Not Specified,BCBS FEP WES criteria apply to patients with unexplained developmental delay/intellectual disability without specific age cutoff; no age-based exclusion applies to this 10-year-old.,Not Specified,BCBS FEP policies generally require an appropriate ordering clinician but do not impose a strict specialty-only ordering requirement for WES in this context; the record shows referral by a cardiologist but policy does not explicitly restrict ordering to a geneticist.,Yes,"BCBS FEP considers WES medically indicated for unexplained developmental delay/intellectual disability after standard first-tier testing is nondiagnostic; the patient has nonsyndromic developmental delay and intellectual disability, which meets the clinical indication.",No,"BCBS FEP requires prior first‑tier genomic testing (chromosomal microarray) for unexplained DD/ID before WES. Only FISH (nondiagnostic) was completed; CMA is not documented, so required prior testing is incomplete.",Not Specified,"While family history (an affected brother) is clinically relevant and present, BCBS FEP WES eligibility does not require specific family history/consanguinity criteria as a hard requirement; policy treats family history as supportive but not mandatory.",Yes,"BCBS FEP expects documentation of pre‑test genetic counseling for WES; the record documents pre‑test counseling and plans for post‑test follow‑up, meeting counseling requirements.",81415,"CPT 81415 corresponds to whole exome sequencing (clinical exome sequencing) for the proband, which matches the requested WES.",No,"Although clinical indication and counseling are met, BCBS FEP requires prior first‑tier testing (chromosomal microarray) for unexplained DD/ID; CMA is not documented (only nondiagnostic FISH), so WES would not meet coverage criteria at this time.",1997,2235,4232
Case18281,baseline,without_policy,iter1,WGS,The clinical note explicitly states the cardiologist has ordered whole genome sequencing (WGS).,Not Specified,UHC WES/WGS criteria are indication-based and do not impose a strict age cutoff; the patient is 6 but policy does not specify age-based exclusion/requirements.,Not Specified,"UHC medical necessity policy requires documentation of clinical indication but does not rigidly restrict ordering to a specific named specialty in all cases; the record shows a treating specialist (cardiologist) placed the order, and the policy does not specifically require a genetics provider.",Yes,"UHC considers WGS medically necessary for individuals with unexplained multiple congenital anomalies or an undiagnosed condition after prior evaluation; this 6‑year‑old has multiple congenital anomalies that do not fit a well‑delineated syndrome, which meets that indication.",No,"UHC typically requires prior appropriate testing (e.g., chromosomal microarray and other targeted tests) before WES/WGS; only Fragile X was reported (nondiagnostic) and no CMA result is documented, so required prior testing appears incomplete.",Yes,The patient has a family history (sibling) of an inborn error of metabolism; UHC criteria consider relevant family history as supportive for genomic testing eligibility.,No,UHC policies require documentation of pre‑test genetic counseling for WES/WGS; the record states no genetic counseling was conducted prior to testing.,81425,"Among the provided CPT options, 81425 corresponds to whole genome sequencing and is the appropriate code for the requested WGS.",No,"Although the indication (multiple congenital anomalies) and positive family history support medical necessity under UHC policy, required prior testing (notably chromosomal microarray) and documented pre‑test genetic counseling are not present; failure to meet these payer prerequisites supports denial/not covered.",1982,1703,3685
Case17196,baseline,without_policy,iter1,CMA,The referral explicitly requests chromosomal microarray (CMA) testing to evaluate longstanding neuropsychiatric presentation.,Not Specified,"BCBS FEP CMA policy is based on clinical indication (unexplained developmental delay/intellectual disability, ASD, or multiple congenital anomalies) rather than a strict age cutoff; no age-based exclusion for CMA is specified in the payer criteria.",Not Specified,BCBS FEP molecular cytogenetic policies generally do not mandate a specific ordering provider specialty for CMA; no provider-specialty requirement is specified in the policy applied to this case.,No,"Under BCBS FEP CMA coverage criteria, testing is medically indicated for unexplained developmental delay/intellectual disability, autism spectrum disorder, or multiple congenital anomalies. The patient has adult-onset neuropsychiatric symptoms (bipolar/schizophrenia/OCD features) without documentation of developmental delay, intellectual disability, ASD, or multiple congenital anomalies, so the clinical indications are not met.",Not Specified,"BCBS FEP CMA criteria do not uniformly require a prior test before CMA (array is often first-line for indicated indications). Although a karyotype was performed and nondiagnostic, payer rules do not specify a mandatory prior test for CMA in this clinical context.",Not Specified,"BCBS FEP CMA coverage hinges on the proband's clinical features; while a sibling had early hearing/visual impairment, the policy does not rely on family history/consanguinity alone as a primary eligibility criterion for CMA in the absence of the proband meeting clinical indications.",No,"BCBS FEP documentation requirements for cytogenomic testing typically require documentation of pre-test genetic counseling/informed consent. The patient has no pre-test genetic counseling documented, so counseling requirements are not met.",81228,"CPT 81228 corresponds to chromosomal microarray analysis (e.g., array CGH or SNP array) and is the appropriate code for CMA.",No,"Based on BCBS FEP coverage criteria, CMA is not supported because the patient does not meet the payer's specified medical indications (no documented developmental delay/intellectual disability/ASD or multiple congenital anomalies) and required pre-test genetic counseling is not documented; therefore the test is not covered.",1992,2101,4093
Case8288,baseline,without_policy,iter1,WES,Patient/family are pursuing whole exome sequencing (WES) after a nondiagnostic chromosomal microarray to evaluate a fetal major congenital cardiac anomaly; the note explicitly states WES is being pursued.,Not Specified,UHC WES criteria are applied by clinical presentation (prenatal/fetal structural anomaly) rather than strict chronological age limits; fetal gestational age (36 weeks) does not conflict with prenatal WES coverage criteria.,Not Answerable,"UHC typically requires ordering by an appropriate qualified provider (genetics specialist, genetic counselor involvement documented). The record shows referral by a developmental pediatrician and genetic counseling sessions but does not explicitly name the ordering provider or their specialty, so provider-eligibility cannot be confirmed from provided information.",Yes,UHC medical-necessity criteria support WES for a fetus with a major structural congenital anomaly (cardiac malformation) when prior CMA is nondiagnostic; patient meets this indication.,Yes,"UHC requires prior chromosome microarray before WES in many prenatal indications; the patient had a CMA that was nondiagnostic, satisfying the prior-test requirement.",Yes,The patient/fetus has relevant family history—an older sibling with an inborn error of metabolism—which is a pertinent family-history criterion in genetic testing eligibility and supports broader testing.,Yes,"UHC commonly requires documented genetic counseling for WES; the parents have had multiple sessions with a genetic counselor, meeting counseling requirements.",81415,"CPT 81415 corresponds to clinical exome sequencing (WES) with interpretation and report, which matches the requested test.",Yes,"Clinical indication (prenatal major cardiac anomaly), nondiagnostic prior CMA, documented genetic counseling, and relevant family history meet UHC WES coverage criteria. (Final approval would be contingent on verification of the ordering provider per UHC policy.)",2018,1570,3588
Case3422,baseline,without_policy,iter1,WES,The clinical note explicitly states consideration of whole-exome sequencing (WES).,Not Specified,Cigna WES criteria are not age-limited in general; no specific age-based exclusion or requirement applies to this adult patient in the policy.,Not Answerable,"Cigna typically requires ordering/consultation by a genetics provider or documentation of genetics involvement for WES. The record states referral by oncology and multiple genetic counselor visits but does not specify who will actually place the WES order, so whether the ordering provider meets payer-specific requirements cannot be determined from the provided information.",No,"Cigna’s WES coverage is generally limited to individuals with features such as developmental delay/intellectual disability, autism with DD/ID, or multiple congenital/anomalous findings or a high suspicion of a Mendelian disorder after prior testing. This patient has a single congenital anomaly (choanal atresia) and no documented DD/ID or additional anomalies, so she does not meet the defined medical indication.",Yes,"Cigna requires prior appropriate testing (e.g., nondiagnostic chromosomal microarray) before WES in many indications. The patient had a nondiagnostic CMA as stated.",No,"Family-history/consanguinity criteria for WES would be met by relatives with similar congenital findings or a known Mendelian condition. The only family history noted is a mother with breast cancer at age 50, which is not relevant to the patient’s choanal atresia or WES eligibility here.",Yes,"Cigna requires documentation of genetic counseling for complex molecular testing; the patient has seen a genetic counselor multiple times, meeting the counseling requirement.",81415,"CPT 81415 corresponds to clinical whole-exome sequencing, which matches the requested WES.",No,"Although prior CMA was nondiagnostic and genetic counseling occurred, Cigna’s coverage criteria require specific clinical indications (e.g., multiple congenital anomalies, DD/ID, or strong suspicion of a Mendelian disorder). The patient has an isolated choanal atresia without additional syndromic features or DD/ID, so WES does not meet medical necessity per the payer policy.",1964,2208,4172
Case5885,baseline,without_policy,iter1,WGS,The patient information explicitly states that whole genome sequencing (WGS) is requested.,Not Specified,"UHC WES/WGS policies do not impose a strict single age cutoff; pediatric WGS is commonly evaluated on clinical indications rather than age alone, and the 11-year-old patient does not conflict with typical payer age language.",Not Specified,Typical UHC policy requires an ordering clinician (physician or qualified provider) but does not universally mandate that the test be ordered only by a genetics specialist; the record shows neurology referral and genetic specialist counseling but it is not specified whether an ordering-provider specialty requirement applies.,Yes,The patient has a major abnormality affecting at least one organ system with neurologic referral and a nondiagnostic Fragile X test; under UHC criteria WGS/WES is indicated for unexplained major congenital/structural abnormalities or neurologic disorders when prior targeted testing is unrevealing.,No,"UHC commonly requires prior appropriate targeted testing (e.g., chromosomal microarray) for developmental/structural anomalies before WES/WGS; only Fragile X testing is documented as completed (nondiagnostic) and no chromosomal microarray or other required prior testing is documented.",Yes,There is a reported family history of long QT syndrome in the mother; this is relevant family history for genetic evaluation and may support broader genomic testing.,Yes,"Pre-test counseling was discussed with a genetic specialist and post-test follow-up plans are in place, satisfying UHC requirements for documented genetic counseling when required for WES/WGS.",81425,"81425 corresponds to clinical whole genome sequencing (WGS), which matches the test requested.",No,"Although medical indication and counseling are met, UHC coverage typically requires completion/documentation of prior required testing (e.g., chromosomal microarray) before approving WGS; because required prior testing beyond Fragile X is not documented, the request would not meet coverage requirements as submitted.",1975,2172,4147
Case14195,baseline,without_policy,iter1,BRCA1/2,Patient was explicitly referred for BRCA1/2 testing per the clinical information.,Not Specified,BCBS_FEP BRCA coverage is driven by personal/family cancer history and clinical criteria rather than a strict age cut‑off; no age‑based exclusion/applicability is specified for BRCA testing and the patient is an adult (18).,Not Specified,The provided information does not indicate any payer requirement for a specific ordering provider specialty; BCBS_FEP policies generally do not limit ordering to a single specialty in the clinical scenario provided.,No,"BCBS_FEP coverage for BRCA1/2 requires qualifying personal or family history of BRCA‑related cancers or a known familial pathogenic variant. The patient has no personal history of breast/ovarian/etc. cancer and the only family history is a maternal uncle with dystonia/ataxia (not a qualifying BRCA‑related cancer), so medical indication for BRCA testing is not met.",Not Specified,BCBS_FEP does not generally require prior diagnostic cytogenetic testing (karyotype) before BRCA testing; the nondiagnostic karyotype is irrelevant to BRCA criteria and no other specific prior tests are mandated in the provided criteria.,No,"Family‑history criteria are specified for BRCA testing (first/second degree relatives with BRCA‑associated cancers, known familial mutation). The documented family history (maternal uncle with neurologic disease) is not a qualifying family history for BRCA coverage.",No,"BCBS_FEP commonly requires documentation of pretest genetic counseling for BRCA testing; the record states no pretest genetic counseling was conducted, so counseling requirements are not met.",Not Specified,"The clinical request is for BRCA1/2 testing, but the provided CPT options do not unambiguously map to standard BRCA sequencing (common BRCA sequence codes such as 81211/81213 are not listed). Therefore a specific CPT from the provided list cannot be confidently selected.",No,"Applying BCBS_FEP BRCA coverage rules: patient lacks qualifying personal/family history of BRCA‑associated cancer and pretest genetic counseling is not documented. Therefore, under payer criteria the BRCA1/2 test would not be covered.",1960,2491,4451
Case2847,baseline,without_policy,iter1,WES,Patient record explicitly states 'whole exome sequencing (WES) is being pursued.',Yes,BCBS FEP WES criteria include infants/children with suspected genetic etiology or severe early‑onset presentation; the patient is a 5‑week‑old infant and therefore meets the pediatric/neonatal age criteria.,Not Specified,BCBS FEP policies typically require qualified ordering and documentation of counseling but do not strictly restrict ordering to a single specialty in the presented policy text; the patient info notes cardiology referral but does not state a prohibited ordering provider.,Yes,Medical necessity criteria for WES under BCBS FEP include infants with severe unexplained early‑onset events or suspected genetic disorders; this infant had a high‑risk unexplained event requiring CPR and thus meets the clinical indication.,Yes,"Policy typically requires prior chromosomal microarray for unexplained congenital/neurologic presentations; the record states prior CMA was nondiagnostic, satisfying this prior testing requirement.",Yes,Family history of mother with a persistent severe immunologic/hematologic disorder is relevant to genetic evaluation and supports eligibility under family history criteria.,Yes,BCBS FEP requires documentation of pre‑test genetic counseling for complex genomic testing; the record documents that pre‑test counseling was completed and post‑test follow‑up is planned.,81415,CPT 81415 corresponds to whole exome sequencing (clinical exome sequencing) and best matches the requested WES.,Yes,"From a BCBS FEP coverage adjudication perspective the patient meets age, medical necessity (severe unexplained early‑onset event), prior testing (CMA nondiagnostic), family history, and counseling requirements — WES is therefore covered.",1999,1615,3614
Case11855,baseline,without_policy,iter1,CMA,The clinical note explicitly states chromosomal microarray (CMA) is being ordered to assess for copy number variants.,Not Specified,UHC CMA criteria do not impose an age limit; age (14) is not a specified eligibility restriction for CMA in payer policy.,Not Specified,UHC CMA coverage does not mandate a specific ordering provider specialty in the policy text; no provider-type restriction is specified for this test.,No,"UHC policy covers CMA for individuals with developmental delay/intellectual disability, autism spectrum disorder, or multiple congenital anomalies. This patient has a single‑organ congenital anomaly without documentation of developmental delay/ID/ASD or multiple anomalies, so documented indications do not meet payer medical-necessity criteria.",Not Specified,"UHC CMA policy does not require prior testing (e.g., karyotype or Fragile X) as a universal precondition; although Fragile X was done, the policy does not list specific required prior tests.",No,Family history noted (maternal aunt with triple‑negative breast cancer) is relevant to hereditary breast cancer testing but is not a family history criterion that supports CMA eligibility per UHC (no family history of CNV/chromosomal abnormalities reported).,Not Specified,"UHC CMA policy does not explicitly mandate pre‑test genetic counseling as a strict coverage criterion; however, the patient did receive counseling from a genetics specialist per the record.",81425,"CPT 81425 corresponds to chromosomal microarray/molecular cytogenetic microarray testing for genome‑wide copy number variants (CMA), which is the test ordered.",No,"Per UHC coverage criteria, CMA is medically indicated for developmental delay/ID, ASD, or multiple congenital anomalies; this patient has a single‑organ congenital anomaly without documented neurodevelopmental disorder or multiple anomalies, so the test does not meet payer medical‑necessity criteria and would not be covered.",2011,2037,4048
Case3465,baseline,without_policy,iter1,WGS,Statement explicitly says whole genome sequencing (WGS) has been ordered.,Yes,UHC pediatric genomic policies apply to children; the patient is 2 years old (meets age-based eligibility for pediatric WGS/WES evaluations).,Yes,Ordering clinician is a medical geneticist and testing was done with pre-test genetic counseling — meets UHC requirements that a genetics provider or appropriate specialist order/coordinate testing.,Yes,UHC criteria list unexplained developmental delay/intellectual disability as an indication for comprehensive genomic testing (WGS/WES); the patient has developmental delay and intellectual disability without a specific syndrome.,No,"UHC typically requires prior first‑line testing (chromosomal microarray and Fragile X for males when indicated) before WGS/WES. Only Fragile X is documented as nondiagnostic; CMA status is not provided, so required prior testing has not been completed.",No,"UHC policies note family history/consanguinity of similar phenotype can support testing. Although there is a family history of Long QT syndrome in the father, this is unrelated to the child’s developmental phenotype and does not constitute relevant family history for neurodevelopmental testing.",Yes,"UHC commonly requires genetic counseling pre- and post-test. Pre-test counseling was completed and post-test counseling is planned, satisfying counseling requirements.",81425,81425 corresponds to whole genome sequencing (WGS) interpretation/reporting and is the appropriate CPT among the provided options.,No,"Although the patient meets clinical indication, age, provider, and counseling requirements, UHC requires prior first‑line testing (notably CMA) before WGS; CMA is not documented as completed, so WGS does not meet coverage criteria at this time.",1981,1484,3465
Case15557,baseline,without_policy,iter1,WGS,The clinical note explicitly states the patient is being evaluated with whole genome sequencing (WGS).,Yes,UHC policies limit WGS/WES indications to pediatric patients in many clinical situations; the patient is 15 years old (pediatric) and therefore meets age-based eligibility for WGS.,Yes,"UHC typically requires ordering clinician involvement plus documented genetics involvement; the patient was referred by neurology and has been seen multiple times by a genetic counselor, satisfying ordering/provider requirements.",Yes,"UHC covers WGS/WES for unexplained congenital anomalies/multiple congenital anomalies or suspected genetic disorder. This patient has a congenital anomaly present since birth and a sibling with a similar anomaly, meeting a medical indication.",No,"UHC generally requires prior appropriate first‑tier testing (e.g., chromosomal microarray) before WGS; the record notes prior FISH was nondiagnostic but does not document completion of CMA or other required prior testing.",Yes,"Family history is relevant: the patient has a sibling with a similar congenital anomaly, which is a documented family history that supports genetic testing per coverage criteria.",Yes,"UHC requires documented pre‑/post‑test genetic counseling for WGS in many cases; the patient has had multiple genetic counseling visits and plans for post‑test counseling, meeting counseling requirements.",81425,81425 corresponds to whole genome sequencing (germline) and is the CPT that best matches the requested WGS.,No,"Although age, indication, provider involvement, family history, and counseling are met, UHC requires completion of specified prior testing (e.g., chromosomal microarray) before WGS; only FISH was done and CMA is not documented, so coverage is not met at this time.",1978,1681,3659
Case4982,baseline,without_policy,iter1,WES,The clinical note explicitly states the patient is being considered for whole exome sequencing (WES).,Not Specified,"UHC WES coverage criteria do not impose a strict age cutoff for exome sequencing; the patient is 11 years old which is within the typical age range evaluated, and no age-based exclusion is specified.",Not Specified,"UHC policies generally require that testing be ordered by an appropriate provider but do not rigidly restrict ordering to a single specialty in the policy language; the ordering provider here (developmental pediatrician) is an appropriate specialist, and the policy does not specify a prohibitive ordering-provider requirement.",Yes,"UHC covers WES for individuals with suspected genetic/neurodevelopmental disorders after appropriate workup; this patient has Hirschsprung disease (congenital anomaly), developmental pediatric evaluation, and a sibling with early-onset epileptic encephalopathy—consistent with a suspected heritable syndromic/neurodevelopmental condition meeting medical indication criteria.",No,UHC WES criteria typically require prior standard testing such as chromosomal microarray (and other targeted testing as indicated). The record documents nondiagnostic FISH but does not document prior chromosomal microarray (CMA) or other required prior tests.,Yes,Family history is relevant: a sibling with epileptic encephalopathy before age three supports a potential heritable condition and meets family-history–relevant criteria in UHC policy.,Yes,"UHC requires documented genetic counseling for WES; the family has met with a genetic counselor multiple times for pre-test counseling with plans for post-test disclosure, satisfying counseling requirements.",81415,The requested test is whole exome sequencing; CPT 81415 corresponds to exome sequencing (clinical WES) and is the appropriate code among the options.,No,"Although the clinical indication, family history, and genetic counseling meet UHC criteria, a required prior test (chromosomal microarray) is not documented. Per UHC coverage rules, required prior testing must be completed and nondiagnostic before WES will be covered.",2007,1683,3690
Case14371,baseline,without_policy,iter1,WES,The clinical note explicitly states the general pediatrician ordered whole exome sequencing (WES).,Yes,"UHC WES criteria specify pediatric patients with unexplained neurodevelopmental disorder/ASD as an eligible population; the patient is 11 years old, which meets pediatric age-based eligibility.",Not Specified,UHC policies define clinical indications and pre-test requirements but do not mandate a single specific ordering specialty in the provided criteria; the ordering clinician is a general pediatrician and no disqualifying specialty restriction is documented.,Yes,"UHC considers WES medically indicated for unexplained neurodevelopmental disorder/ASD in children; the patient has complex neurodevelopmental disorder and autism spectrum disorder, meeting a covered clinical indication.",No,"UHC WES coverage generally requires prior appropriate testing (chromosomal microarray and Fragile X testing when indicated). Fragile X testing was nondiagnostic, but chromosomal microarray status is not documented — required prior CMA has not been shown to be completed.",Yes,The patient has a relevant family history (maternal aunt with persistent severe immunologic disorder) that could inform interpretation; this family history is present in the record.,Yes,"UHC requires pre- and post-test genetic counseling for WES; the family met with a genetic counselor before testing and has plans for post-test follow-up, satisfying counseling requirements.",81415,"CPT 81415 corresponds to diagnostic exome sequencing (proband only), which matches the requested WES.",No,"Although age, clinical indication, counseling, and family history requirements are met, UHC requires completion/documentation of prior testing (notably chromosomal microarray) before WES; that prior test is not documented, so coverage would be denied pending completion of required prior testing.",1983,1497,3480
Case15202,baseline,without_policy,iter1,BRCA1/2,Patient was referred specifically for BRCA1 and BRCA2 testing to evaluate hereditary breast/ovarian cancer risk.,No,"BCBS_FEP BRCA policies include age-related criteria for personal history (e.g., early-onset breast cancer) — the patient is 65 and does not meet typical age-based indications for BRCA testing in the absence of other qualifying features.",Yes,Payer policies require ordering by an appropriate clinician and documentation of genetic counseling; the test was ordered by the patient's gynecologist (an appropriate ordering physician) and pre-test counseling was completed with a genetic specialist.,No,"BCBS_FEP BRCA medical indications are specific (personal history of epithelial breast carcinoma, ovarian cancer, male breast cancer, early-onset disease, or qualifying family history). A malignant phyllodes tumor is not a BRCA-associated tumor, so the patient does not meet defined clinical indications.",Not Specified,BCBS_FEP BRCA criteria do not generally mandate prior genetic tests for this scenario; no specific prior-test requirement applicable to this patient (the prior Fragile X test is irrelevant).,No,"BCBS_FEP BRCA family-history criteria require relatives with breast/ovarian/pancreatic/prostate cancers or known BRCA mutation. The reported sister has an immunologic/hematologic disorder, which is not a BRCA-relevant family history.",Yes,"BCBS_FEP requires documentation of pre-test genetic counseling for hereditary cancer testing; the patient completed pre-test counseling with a genetic specialist and has plans for post-test follow-up, satisfying counseling requirements.",Not Specified,"Standard BRCA CPT codes (e.g., 81211/81213 for BRCA1/BRCA2 sequencing) are not among the provided options, so none of the listed codes exactly corresponds to BRCA1/2 testing.",No,"Under BCBS_FEP BRCA coverage criteria the patient lacks a BRCA-associated personal cancer history and lacks a relevant family history; although counseling and ordering provider requirements are met, the absence of qualifying medical/family indications means the test is not covered.",1990,2462,4452
Case8621,baseline,without_policy,iter1,WES,The patient is explicitly described as undergoing whole exome sequencing (WES) to seek a unifying diagnosis.,Not Specified,UHC WES criteria are driven by clinical indication (neurodevelopmental disorder) rather than a strict numeric age cutoff; the record documents a pediatric patient (2 years) but the policy does not specify an absolute age limit.,Not Specified,UHC coverage generally requires an appropriate ordering clinician but does not mandate a specific specialty in all cases; the information gives the ordering provider (oncologist) but the policy does not explicitly restrict orders to a geneticist.,Yes,"UHC permits WES for individuals with unexplained complex neurodevelopmental disorders/autism spectrum disorder when a unifying genetic diagnosis is sought; the patient has a complex neurodevelopmental disorder with autism, meeting that clinical indication.",Yes,"UHC typically requires prior standard testing such as chromosomal microarray before WES for developmental disorders; the patient had prior CMA testing that was nondiagnostic, satisfying this requirement.",Yes,"Family history criteria (having a relative with congenital anomaly or similar phenotype) can support genetic testing eligibility; the family reports an uncle with a congenital anomaly, which is relevant.",Yes,"UHC requires documentation of genetic counseling for WES; the family has met with a genetic counselor multiple times with pre-test counseling completed and plans for post-test follow-up, meeting counseling requirements.",81415,"CPT 81415 corresponds to clinical whole exome sequencing (WES), which is the test requested.",Yes,"Per UHC criteria the patient has an appropriate clinical indication (complex neurodevelopmental disorder/autism), required prior testing (nondiagnostic CMA) is documented, genetic counseling is completed, and relevant family history is present — together these meet coverage criteria for WES.",1988,1693,3681
Case14141,baseline,without_policy,iter1,WES,The note explicitly states 'whole exome sequencing (WES) is planned' to investigate an underlying genetic etiology.,Not Specified,"BCBS FEP WES coverage policies do not impose a strict age cutoff for diagnostic WES in patients with unexplained congenital anomalies/developmental delay; the patient is 7 years old which is within typical pediatric indications, but no specific age criterion is stated.",Not Specified,FEP WES policies require appropriate documentation of medical necessity but generally do not restrict ordering to a single provider specialty; the referring oncologist ordering evaluation is acceptable and no specific ordering-provider limitation is specified in the policy.,Yes,"FEP clinical criteria support WES for patients with multiple congenital anomalies and/or global developmental delay when a genetic etiology is suspected; this patient has multiple congenital anomalies and a family history of developmental delay, meeting the medical indication.",Yes,"BCBS FEP requires prior chromosomal microarray (CMA) as first‑line testing for unexplained developmental delay/congenital anomalies; the record states CMA was performed and reported as nondiagnostic, satisfying the prior‑test requirement.",Yes,Family history of global developmental delay in a sibling is documented; FEP policies list a family history of similar neurodevelopmental disorders as relevant supportive information for diagnostic WES eligibility.,Yes,"FEP WES guidance requires pre‑test genetic counseling and arrangements for post‑test counseling; the record confirms pre‑test counseling was completed and post‑test follow‑up is arranged, meeting counseling requirements.",81415,"CPT 81415 corresponds to clinical whole exome sequencing (WES) with interpretation and report, which matches the requested test.",Yes,"Per BCBS FEP WES coverage criteria: the patient has a compatible clinical indication (multiple congenital anomalies/developmental concerns), prior CMA was nondiagnostic, pre‑test counseling documented, and supportive family history—thus the test meets FEP medical necessity criteria and is covered.",1983,1472,3455
Case6747,baseline,without_policy,iter1,WGS,Clinical note explicitly states whole genome sequencing (WGS) is being ordered by the medical geneticist.,Yes,"BCBS_FEP WGS criteria apply to pediatric patients with congenital anomalies/developmental concerns; patient is 12 years old, which meets pediatric age-based eligibility.",Yes,"BCBS_FEP requires that WGS be ordered by an appropriate genetics provider for complex pediatric cases; the ordering provider is a medical geneticist, which satisfies this requirement.",Yes,"Medical necessity criteria include multiple congenital anomalies and suspected genetic etiology/developmental concerns—patient has multiple congenital anomalies and a suspected genetic cause, meeting indication.",Yes,"BCBS_FEP generally requires prior chromosomal microarray for developmental/congenital anomaly evaluation; CMA was previously performed and was nondiagnostic, satisfying prior-testing requirement.",Yes,Family history of a sibling with developmental delay is relevant and supports testing per BCBS_FEP criteria that consider family history when evaluating genetic testing necessity.,Yes,"BCBS_FEP requires genetic counseling pre- and post-testing for WGS; pre-test counseling completed and post-test counseling is planned, meeting counseling requirements.",81425,CPT 81425 corresponds to whole genome sequencing (proband) and best matches the requested WGS.,Yes,"All BCBS_FEP coverage criteria are met: appropriate age, qualifying clinical indication (multiple congenital anomalies), nondiagnostic prior CMA, ordering by a medical geneticist, relevant family history, and completed pre-test counseling — therefore WGS is covered.",1966,929,2895
Case811,baseline,without_policy,iter1,WES,The case explicitly states whole exome sequencing (WES) is being pursued to evaluate an underlying genetic etiology.,Not Specified,BCBS FEP WES coverage is based on clinical indication (congenital anomalies/early-onset neuro disorder) rather than a strict age cutoff; no age-specific exclusion is documented and the infant age (7 weeks) does not conflict with policy.,Not Specified,BCBS FEP policies typically require an appropriate ordering clinician and documentation but do not mandate a single specific specialty for ordering WES; the provided record does not state a specific required ordering specialty.,Yes,"BCBS FEP covers WES for unexplained congenital anomalies or early-onset neurologic/movement disorders. The patient has early-onset dystonia/ataxia/hemiplegic episodes and a nondiagnostic CMA, meeting clinical indication criteria.",Yes,"BCBS FEP generally requires prior chromosomal microarray for congenital anomalies/neurologic presentations; a CMA was performed and reported nondiagnostic, satisfying the prior-test requirement.",Yes,"Family-history criteria are relevant for WES eligibility; the patient has an older sibling with multiple congenital anomalies, which supports testing per BCBS FEP indications.",Yes,BCBS FEP requires documented pre-test genetic counseling for WES in many cases; the record states pre-test counseling was completed with a genetic counselor and post-test follow-up is planned.,81415,"CPT 81415 corresponds to exome sequencing (whole exome), which matches the requested WES.",Yes,"Under BCBS FEP policy the case meets coverage criteria: infant with early-onset movement/neurologic disorder and family history of congenital anomalies, prior nondiagnostic CMA, and documented pre-test genetic counseling; therefore WES is medically necessary and covered.",2018,1757,3775
Case7604,baseline,without_policy,iter1,WGS,"The clinical note explicitly states ""whole genome sequencing (WGS) has been ordered.""",Yes,UHC genomic testing policies permit WGS for pediatric/neonatal patients with unexplained multiple congenital anomalies; the patient is a neonate with multisystem congenital anomalies and therefore meets age-related eligibility.,Not Specified,The record shows a neurologist referred/ordered testing; UHC policies typically require an appropriate treating/provider but do not universally mandate a single specialty in all cases. The provided information does not state a payer-imposed mandatory ordering specialty.,Yes,"UHC covers WGS when there is an unexplained, suspected genetic etiology such as multiple congenital anomalies affecting several organ systems; the neonate meets this clinical indication.",No,"UHC clinical policies generally require prior first‑tier cytogenetic testing such as chromosomal microarray (CMA) before WGS for congenital anomalies. The patient had FISH (nondiagnostic) but there is no documentation of prior CMA, so required prior testing was not completed.",Yes,The patient has an affected older sibling with multiple congenital anomalies; family history is relevant and supportive under UHC criteria for pursuing genomic testing.,No,"UHC typically requires documentation of pre‑test genetic counseling for clinical genomic testing. The family declined genetic counseling, so counseling requirements are not met.",81425,CPT 81425 corresponds to whole genome sequencing (germline) and is the appropriate code for WGS.,No,"Although the patient meets medical indication, age, and has supportive family history, UHC requires prior appropriate cytogenetic testing (e.g., CMA) and documentation of genetic counseling; neither CMA nor counseling is documented, so coverage would be denied per payer criteria.",1973,1551,3524
Case950,baseline,without_policy,iter1,WES,The case text explicitly states 'whole exome sequencing (WES) is being pursued to look for an underlying genetic cause.',Not Specified,UHC WES coverage criteria are applied based on clinical presentation rather than strict age cutoffs; no payer-specific age exclusion is stated and the patient (38 y) with onset before age 3 meets clinical-age context but the policy does not set a numeric age requirement.,Yes,"UHC typically requires an appropriate ordering clinician (e.g., geneticist or neurologist); the patient is being evaluated by a medical geneticist, which satisfies ordering-provider requirements.",Yes,"UHC allows WES for unexplained early-onset epileptic encephalopathy or refractory/undiagnosed epileptic encephalopathies; the patient has unexplained epileptic encephalopathy with onset before age 3, meeting the medical indication.",No,"UHC commonly requires prior appropriate testing (e.g., chromosomal microarray and/or targeted epilepsy multigene panel) before WES; this patient has a nondiagnostic karyotype and has not had an epilepsy multigene panel or CMA, so required prior testing is incomplete.",No,"Family history noted (uncle with prostate cancer) is not relevant to eligibility for WES for epileptic encephalopathy, and no consanguinity or relevant family neurologic history is reported.",Yes,"UHC requires documentation of pre- and post-test genetic counseling for complex genomic testing; the patient has seen a genetic counselor multiple times and has plans for post-test counseling, meeting counseling requirements.",81415,CPT code 81415 corresponds to whole exome sequencing (clinical exome sequencing) and is the appropriate code for WES.,No,"Although clinical indication, provider, and counseling requirements are met, UHC coverage requires completion/documentation of required prior testing (e.g., CMA and/or epilepsy multigene panel) before approval of WES; those prior tests have not been completed, so WES is not covered at this time.",2012,1676,3688
Case17822,baseline,without_policy,iter1,WGS,Patient information explicitly states whole genome sequencing (WGS) has been ordered as the next-tier diagnostic test.,Yes,UHC policy defines WES/WGS coverage for pediatric patients with unexplained multiple congenital anomalies or developmental concerns; the patient is a 13-year-old (pediatric) and meets the age-based eligibility.,Yes,"UHC requires ordering by an appropriate qualified provider (e.g., medical geneticist); the order was placed by a medical geneticist, satisfying provider requirements.",Yes,UHC medical necessity criteria include unexplained multiple congenital anomalies affecting different organ systems as an indication for WGS; the patient meets this clinical criterion.,Yes,"UHC typically requires prior chromosomal microarray (CMA) testing before WES/WGS for congenital anomaly presentations; the record states a nondiagnostic CMA was completed, meeting prior test requirements.",Yes,"Family history criteria (affected first‑degree relative or similar phenotype) are relevant for WES/WGS consideration; the patient has a sibling with short stature, which is a relevant family history.",No,"UHC generally requires documentation of pretest genetic counseling/informed consent for WES/WGS; the family declined genetic counseling prior to testing, so counseling requirements are not met.",81425,"Among listed CPT options, 81425 corresponds to whole genome sequencing performed for diagnostic purposes.",No,"Although age, provider, clinical indication, prior CMA, and family history meet UHC criteria, the required pretest genetic counseling/documentation was declined and thus a key coverage requirement is unmet, making the test not covered per policy.",1985,1713,3698
Case9408,baseline,without_policy,iter1,WES,The note explicitly states the patient is undergoing whole exome sequencing (WES) requested by a medical geneticist for evaluation of epileptic encephalopathy.,Not Specified,"Blue Cross Blue Shield FEP WES coverage policies do not impose a strict age cutoff for diagnostic WES; the policy is indication-based (early-onset epileptic encephalopathy is eligible). The patient is 17, but age-specific eligibility is not specified in the payer criteria.",Yes,"FEP policies generally require ordering or authorization by an appropriate specialist (e.g., medical geneticist/genetics provider). The test was ordered by a medical geneticist, meeting provider requirements.",Yes,"FEP WES coverage criteria include individuals with unexplained epileptic encephalopathy with onset in early childhood; the patient has epileptic encephalopathy with onset before age 3, which meets a listed medical indication.",Yes,"FEP criteria for WES typically expect prior chromosomal microarray (CMA) testing for neurodevelopmental/epilepsy indications; the record states CMA was previously performed and was nondiagnostic, satisfying prior test requirements.",No,"While family history of a similar neurologic disorder can support eligibility, the documented family history is a maternal severe immunologic/hematologic disorder, which is not a relevant family history for epilepsy/epileptic encephalopathy per FEP criteria.",Yes,"FEP WES policies require pre-test genetic counseling and plans for post-test counseling; the record documents pre-test counseling and planned post-test follow-up with a genetic counselor, meeting counseling requirements.",81415,CPT 81415 corresponds to clinical exome sequencing (WES) for a proband and is the appropriate code for the requested test.,Yes,"Under Blue Cross Blue Shield FEP criteria the patient meets indication (early-onset epileptic encephalopathy), required prior testing (nondiagnostic CMA), ordering provider requirements (medical geneticist), and counseling requirements; therefore WES is covered.",1998,1668,3666
Case3592,baseline,without_policy,iter1,CMA,The case explicitly states chromosomal microarray (CMA) testing is being requested.,Not Specified,Cigna CMA coverage is not age limited in usual policy language for developmental disorders; no specific age exclusion or minimum is stated for CMA in this clinical context.,Not Specified,Cigna's CMA policy typically does not mandate a particular ordering provider specialty; no provider specialty requirement is specified in the provided information.,Yes,"Patient has unexplained neonatal-onset epileptic encephalopathy (a neurodevelopmental presentation). Cigna's CMA coverage criteria support CMA for unexplained developmental/neurodevelopmental disorders, so the clinical indication is met.",Not Specified,"CMA policy does not generally require prior testing before initial CMA. Although a prior CMA was already performed and was nondiagnostic (noted in the record), Cigna policy language about required prior tests (for an initial CMA) is not specified in the provided information.",Not Specified,"The patient does have a relevant family history (an older sibling with unexplained developmental regression), but Cigna's CMA criteria do not make family history a required eligibility criterion in the usual policy wording; family history is supportive but not a formal specified requirement.",Not Specified,"Although pre-test counseling by a genetics specialist was discussed (and post-test follow-up planned), Cigna's CMA coverage criteria do not explicitly mandate specific documented genetic counseling as a gating requirement in the typical policy statements provided here.",81228,CPT 81228 corresponds to chromosomal microarray/cytogenomic microarray testing (CMA) in standard coding mappings; that best matches the requested test.,No,"While the patient’s presentation meets clinical indications for CMA, Cigna policy generally does not cover repeat CMA after a prior nondiagnostic CMA unless new, clearly documented clinical findings or other qualifying changes are present. Here a prior CMA was nondiagnostic and no new qualifying features are documented; additionally an epilepsy gene panel or WES may be the more appropriate next step. Therefore, under Cigna criteria the requested repeat CMA is not covered.",1990,2769,4759
Case17929,baseline,without_policy,iter1,CMA,The patient information explicitly states that 'tumor chromosomal microarray (CMA) testing has been requested' to assess for genomic imbalance.,Not Specified,"UnitedHealthcare CMA coverage criteria are indication-based (congenital anomalies, developmental delay, etc.) and do not impose a specific age cutoff; no age-based restriction is specified for this CMA request and the child is 7 years old.",Not Specified,"Payer criteria do not mandate a narrowly defined ordering provider specialty for CMA (ordering by a treating physician or genetics/neurology is acceptable). The referral is from a neurologist, which is appropriate, but explicit specialty requirements are not specified in the provided criteria.",Yes,"UHC covers CMA for evaluation of unexplained major congenital anomalies/structural abnormalities or multisystem findings; this 7-year-old is being evaluated for a major abnormality affecting at least one organ system and thus meets the medical indication for CMA. Prior karyotype was nondiagnostic, supporting further genomic imbalance testing.",Not Specified,"Payer guidance typically allows CMA as first‑tier testing for congenital anomalies and does not universally require prior karyotype; although a karyotype was done and nondiagnostic in this case, specific prior‑test requirements are not specified for coverage in the provided criteria.",Not Specified,"Family history of a hereditary breast/ovarian cancer BRCA1/2 variant is documented, but CMA eligibility criteria do not rely on BRCA family history or consanguinity; family history criteria relevant to CMA are not specified in the provided payer criteria.",Not Specified,"While genetic counseling is documented (multiple pretest sessions and planned post-test follow-up), payer policy does not explicitly require a specific documented counseling process as a hard coverage criterion for CMA in the provided criteria.",81228,CPT 81228 corresponds to chromosomal microarray analysis (constitutional) and is the appropriate billing code for CMA testing.,Yes,"Under UHC coverage criteria CMA is covered for evaluation of unexplained major congenital/structural abnormalities or multisystem findings; this patient has a major organ system abnormality and a nondiagnostic karyotype, meets medical necessity, and therefore the requested CMA is covered.",1994,2221,4215
Case12834,baseline,without_policy,iter1,CMA,The clinical note explicitly states that chromosomal microarray (CMA) testing has been ordered.,Not Specified,Cigna CMA coverage is driven by phenotype (developmental delay/intellectual disability/ASD/multiple congenital anomalies) rather than a strict age cutoff; no age-based exclusion is specified and a 16-year-old falls within usual covered ages.,Not Specified,Cigna policies require an order from a qualified provider but do not rigidly specify a single required specialty for CMA orders; the ordering provider is a developmental pediatrician which is an appropriate clinician but the policy does not list a specific specialty requirement.,Yes,CMA is a covered diagnostic test for individuals with unexplained complex neurodevelopmental disorder affecting multiple systems (developmental delay/intellectual disability/ASD or multisystem congenital anomalies); the 16‑year‑old has a complex neurodevelopmental disorder meeting those clinical indications.,Yes,"Cigna coverage pathways commonly expect appropriate prior/screening tests when indicated (e.g., Fragile X testing for developmental delay where appropriate); the record documents prior Fragile X testing that was nondiagnostic, satisfying that prior-test consideration.",Not Specified,"CMA eligibility is based primarily on the proband's phenotype; while a family history of a movement disorder is present (maternal uncle with dystonia/ataxia), Cigna CMA criteria do not specify family history/consanguinity as a required eligibility element for CMA in this context.",Not Specified,Cigna generally recommends genetic counseling for genomic testing but its CMA policy does not universally mandate documented pre‑test genetic counseling as a strict coverage precondition; the record notes no documented counseling but the policy does not explicitly require it for coverage.,Not Specified,None of the provided CPT options clearly correspond to chromosomal microarray in standard coding lists (CMA is typically reported with microarray-specific codes not listed here); the listed codes better map to sequencing/exome/genome tests.,No,"Although the patient meets clinical indications and prior Fragile X was completed, the requisition specifies a tumor-type (somatic) assay rather than a germline CMA. Cigna adjudication requires appropriate germline test designation for coverage of CMA for developmental/neurodevelopmental indications; the tumor/somatic designation on the order would lead to denial unless corrected to a germline CMA order and appropriate billing.",1991,2509,4500
Case4604,baseline,without_policy,iter1,WES,The clinical note explicitly states whole exome sequencing (WES) is being requested to evaluate the child with developmental delay/intellectual disability.,Not Specified,BCBS_FEP WES coverage criteria are based on clinical presentation (unexplained DD/ID) rather than an age cutoff; no payer-specific age restriction is specified and the patient is within a pediatric age group (6 yrs).,Not Specified,"The provided payer criteria do not mandate a specific ordering provider specialty in this case; documentation shows referral by PCP and pre-test counseling by a genetic counselor, which meets typical provider/counseling expectations but no strict specialty requirement is specified.",Yes,Patient has unexplained developmental delay/intellectual disability and a nondiagnostic prior CMA — this matches BCBS_FEP indications for WES for DD/ID when prior first‑line testing was nondiagnostic.,Yes,"BCBS_FEP requires prior chromosomal microarray as a first‑line test for DD/ID; the record states CMA was performed and nondiagnostic, satisfying prior test requirements.",Yes,"Family history is relevant: an older sibling with moderate–severe intellectual disability is documented, which supports genetic testing per coverage considerations for familial DD/ID.",Yes,"BCBS_FEP commonly requires documentation of pre‑test genetic counseling for WES; the record documents pre‑test counseling by a genetic counselor and plans for post‑test follow‑up, meeting counseling requirements.",81415,CPT 81415 corresponds to clinical whole exome sequencing (sequencing and interpretation) and is the appropriate code for the requested WES.,Yes,"All key BCBS_FEP coverage criteria are met: appropriate clinical indication (unexplained DD/ID), required prior CMA nondiagnostic, relevant family history, and documented pre‑test genetic counseling — therefore WES is covered.",1995,1829,3824
Case8661,baseline,without_policy,iter1,WGS,The clinical note explicitly states whole genome sequencing (WGS) is requested to investigate a possible genetic cause.,Not Specified,UHC policies do not impose a strict single age cutoff for WGS; coverage criteria are clinical (pediatric presentations are commonly considered) rather than age-limited in the documentation provided.,Not Specified,There is no payer-specific requirement in typical UHC WES/WGS policy that the ordering clinician must be a genetics specialist; the referral from the child's neurologist meets usual ordering norms and no specialty restriction is specified.,No,"UHC WES/WGS criteria generally require documented clinical indications such as unexplained developmental delay/intellectual disability, multiple congenital anomalies, progressive neurodegenerative disorder, or a highly heterogeneous condition after appropriate prior testing. This patient has isolated significant childhood hearing/visual impairment (with a family history of epileptic encephalopathy) but does not clearly meet those specific listed indications as documented, and required prior targeted testing is not documented.",No,UHC guidance commonly requires prior appropriate testing (for example chromosomal microarray and disorder-specific/gene-panel testing for isolated hearing loss) before WES/WGS. Only Fragile X testing (nondiagnostic) is documented; CMA and appropriate targeted gene-panel testing for hearing/vision loss are not documented as completed.,Yes,"A sibling had early-onset epileptic encephalopathy (<3 years), which is a relevant family history that payers' criteria consider when assessing genetic testing necessity for a proband.",No,"UHC and most payers require documented pre-test genetic counseling for WES/WGS or documentation why it was not possible. Counseling was offered but explicitly declined pre-test, so the requirement for documented pre-test counseling is not met.",81425,81425 corresponds to whole genome sequencing (WGS) analysis and interpretation and is the CPT most appropriate for the requested test.,No,"Under UHC WES/WGS coverage criteria the clinical indication and required prior testing (e.g., CMA and appropriate targeted panels) and documented pre-test genetic counseling are not met; therefore WGS is not covered as requested at this time.",2001,2081,4082
Case6451,baseline,without_policy,iter1,WGS,The clinical note explicitly states whole genome sequencing (WGS) is being pursued.,Yes,UHC WGS/WES policies apply pediatric criteria (no minimum age prohibiting testing); the patient is a 7‑week‑old infant and therefore meets age-based pediatric eligibility.,Not Specified,"UHC medical policies require an ordering clinician but do not universally restrict ordering to a specific single specialty in all situations; the record shows a developmental pediatrician is ordering, which is an appropriate treating specialist, but the policy language about a required specialty is not explicit here.",Yes,UHC criteria list unexplained severe neonatal/infant hypotonia or suspected genetic neurodevelopmental disorder as appropriate indications for comprehensive genomic testing; the infant has significant hypotonia meeting a defined clinical indication.,No,"UHC generally requires prior standard cytogenomic testing (typically chromosomal microarray and/or other first‑line tests) to be nondiagnostic before WGS; only a karyotype (nondiagnostic) was performed — CMA was not documented, so required prior testing was not completed.",Not Specified,"While family history (affected relatives) can support genetic testing, UHC WGS criteria do not make a maternal hematologic/immunologic history a formal required criterion here; the record notes the mother’s disorder but the policy does not explicitly hinge coverage on this detail.",Yes,UHC requires documentation of pre‑test genetic counseling for comprehensive genomic testing; the record states pre‑test counseling was completed and post‑test genetics follow‑up is planned.,81425,"CPT 81425 corresponds to whole genome sequence analysis (WGS), which matches the ordered test.",No,"Although age, clinical indication (infant hypotonia), counseling, and test type match UHC criteria, a required prior cytogenomic test (chromosomal microarray) was not documented (only a nondiagnostic karyotype), so per UHC coverage rules the WGS request would not meet prior‑test requirements and is not covered as submitted.",1975,2250,4225
Case19255,baseline,without_policy,iter1,BRCA1/2,Patient was referred specifically for BRCA1/2 testing to evaluate hereditary breast/ovarian cancer predisposition.,Yes,"UHC BRCA coverage includes individuals with early-onset or multiple primary breast cancers; the patient is 38 and has two separate primary breast cancers, satisfying age-related/early-onset criteria.",Yes,"UHC allows ordering by treating physicians when appropriate and requires documentation of pre-test genetic counseling; the record indicates pre-test counseling with a genetic specialist, meeting ordering/counseling-related requirements.",Yes,"UHC medical indications for BRCA testing include history of two primary breast cancers and/or early-onset breast cancer; the patient has two separate primary breast cancers, meeting a defined medical indication.",Not Specified,UHC does not generally require prior unrelated cytogenetic/FISH testing before BRCA1/2 germline testing; the provided information notes a nondiagnostic FISH but no payer-required prior test is specified.,Yes,"UHC criteria consider relevant family history (including prostate cancer in a first-degree relative) as supporting evidence for BRCA testing; the patient has a father with metastatic prostate cancer, which is relevant.",Yes,"UHC requires documentation of pre-test genetic counseling for BRCA testing; the patient had pre-test counseling with a genetic specialist, meeting this requirement.",Not Specified,"The submission specifies BRCA1/2 testing but does not provide a CPT code. None of the supplied CPT options clearly correspond to the standard BRCA1/2 single-gene CPT codes, so the best match is not specified.",Yes,"Based on UHC coverage criteria (multiple primary breast cancers, early age, relevant family history) plus documented pre-test genetic counseling, BRCA1/2 testing is medically indicated and covered.",1972,1945,3917
Case2211,baseline,without_policy,iter1,BRCA1/2,The referral explicitly requests BRCA1 and BRCA2 (breast cancer susceptibility) testing.,Not Specified,UHC BRCA coverage is driven by personal/family history and presence of a known familial pathogenic variant rather than strict age cutoffs; no age-based exclusion or specific age requirement is specified for BRCA testing in this clinical context.,Not Specified,UHC policies typically permit physician-ordered hereditary cancer testing; no payer-specific ordering-provider specialty limitation is stated in the provided information.,Yes,Patient has a known BRCA2 pathogenic variant in the mother and multiple affected relatives plus a personal history of a primary solid tumor — meets UHC medical indication criteria for BRCA testing (known familial mutation and strong family/personal cancer history).,Not Specified,"There are no required prior laboratory tests documented that must be completed before BRCA testing in this scenario; the record states no prior genetic testing, which is acceptable given the clinical indication.",Yes,Family history is directly relevant: mother carries a known BRCA2 pathogenic variant and there are at least two additional affected blood relatives on the same side — satisfies family-history/known-familial-variant criteria.,Yes,"Pre-test genetic counseling was completed with a genetic specialist and post-test follow-up is planned, meeting UHC counseling expectations for hereditary cancer testing.",81162,"Given a known familial BRCA2 pathogenic variant, the appropriate covered test is targeted single-site familial variant analysis (CPT 81162) rather than full BRCA sequencing.",Yes,"Patient meets payer clinical criteria (known familial BRCA2 pathogenic variant, multiple affected relatives, personal cancer history), counseling is documented, and the appropriate targeted familial-variant test (81162) would be covered by UHC.",2000,2070,4070
Case18882,baseline,without_policy,iter1,WES,The patient information explicitly states whole exome sequencing (WES) is being requested.,Not Specified,UHC WES policies do not impose a strict age cutoff for WES; the child is 8 years old but age-based eligibility is not specified in the payer criteria.,Not Specified,"UHC policies typically do not mandate a narrowly defined ordering provider specialty for WES beyond an appropriate clinician; the test was ordered by a developmental pediatrician (an appropriate specialist), and the policy does not explicitly restrict ordering to a genetics provider.",Yes,"UHC covers WES for individuals with unexplained multiple congenital anomalies or multisystem involvement suggestive of a genetic disorder; this 8‑year‑old has multiple congenital anomalies affecting several organ systems, which meets that clinical indication.",No,"UHC’s WES coverage generally requires prior first‑tier testing (e.g., chromosomal microarray) or documentation of nondiagnostic appropriate prior testing. The record notes only nondiagnostic FISH; no CMA or equivalent prior testing is documented, so required prior testing has not been completed.",Not Specified,"While a positive family history (mother with long QT) is noted and may be clinically relevant, UHC WES coverage criteria do not generally require specific family history/consanguinity criteria for WES eligibility.",No,"UHC expects documentation of informed consent/genetic counseling for WES; the family declined pre‑test genetic counseling (only agreed to post‑test counseling), so the documented counseling requirement is not met.",81415,"CPT 81415 corresponds to clinical exome sequencing (proband only), which matches the requested WES for this single affected child.",No,"Although the clinical indication (multisystem congenital anomalies) supports WES, coverage prerequisites are not met: required prior testing (e.g., chromosomal microarray) is not documented and pre‑test genetic counseling/documentation was declined. Under UHC WES policy these deficiencies would render the request non‑covered.",1978,1734,3712
Case14408,baseline,without_policy,iter1,BRCA1/2,The clinical note states the patient was referred specifically for BRCA1/2 testing.,Not Specified,Cigna BRCA coverage criteria do not impose a strict upper or lower age cutoff for BRCA testing in adults; no age-based exclusion applies to this 75-year-old in the policy.,Not Specified,Cigna policies require documented genetic counseling but do not restrict ordering to a specific medical specialty; the ordering family medicine physician with documented pre-test counseling meets typical provider requirements.,Yes,Cigna covers BRCA testing when there is a close relative with male breast cancer (first‑degree relative); the patient's brother with breast cancer meets a defined medical indication.,Not Specified,"While Cigna often prefers testing an affected relative first when available, the policy also specifies family-history patterns (including a male breast cancer in a first‑degree relative) that allow testing of the proband without prior genetic testing—no specific prior test completion is required here.",Yes,"Family history is directly relevant: a brother (first‑degree relative) with breast cancer — i.e., male breast cancer — is a criterion supporting BRCA testing under Cigna policy.",Yes,"Cigna requires documentation of pre‑test genetic counseling for BRCA testing; the record states pre‑test counseling was completed and post‑test follow-up is planned, satisfying counseling requirements.",81277,"Among the provided CPT options, 81277 most closely corresponds to gene‑specific BRCA testing (the listed choices do not include CPT 81211/81213 which are BRCA1/2 codes), so 81277 is the best match from the supplied set.",Yes,"Based on Cigna coverage criteria the patient meets a covered family‑history indication (first‑degree relative with male breast cancer), has documented pre‑test counseling, and no disqualifying age/provider/prior‑test barriers are present; therefore BRCA1/2 testing is covered.",1957,2554,4511
Case4262,baseline,without_policy,iter1,WES,The clinical note explicitly states diagnostic whole exome sequencing (WES) is being requested.,Not Specified,BCBS FEP WES coverage criteria do not impose a strict age cutoff for diagnostic WES in infants with congenital anomalies; the patient is 5 weeks old which is compatible but age-specific criteria are not specified.,Not Specified,"BCBS FEP policies typically require an appropriate ordering physician and documentation (and often genetic counseling) but do not universally restrict ordering to a genetics specialist; the record shows an oncologist referral and genetics involvement planned, but no explicit payer specialty requirement is stated.",Yes,BCBS FEP considers WES medically indicated for patients with multiple congenital anomalies not fitting a well-delineated genetic syndrome or when a suspected monogenic disorder is present; the infant has multiple congenital anomalies meeting that indication.,No,"BCBS FEP generally requires prior appropriate cytogenomic testing (chromosomal microarray) or other indicated prior tests to be nondiagnostic before WES; the record shows only a nondiagnostic karyotype (not CMA), so required prior testing has not been completed.",No,Family history reported (sibling with a brief resolved unexplained event) is not a clear relevant family history or consanguinity that meets WES-specific family-history eligibility criteria; no qualifying family history is documented.,Yes,BCBS FEP requires documentation of pre-test genetic counseling for diagnostic WES; the record states pre-test genetic counseling was completed and post-test follow-up with genetics is planned.,81415,CPT 81415 corresponds to clinical whole exome sequencing (proband-only or single exome) which matches the requested diagnostic WES.,No,"Although the indication and counseling meet BCBS FEP coverage intent for WES, required prior cytogenomic testing (chromosomal microarray) has not been documented as nondiagnostic (only karyotype was nondiagnostic); per payer criteria lack of required prior testing means coverage is not supported at this time.",1990,1860,3850
Case10363,baseline,without_policy,iter1,WGS,The case text explicitly states whole genome sequencing (WGS) is being pursued.,Not Specified,UHC WES/WGS policies do not impose a strict age cutoff for testing in symptomatic patients with suspected genetic disorders; the patient is a child (age 7) but the policy does not define an age-based exclusion or specific age requirement.,Not Specified,UHC typically requires an appropriate ordering clinician (physician or qualified genetics professional) but the policy does not mandate a single specialty; the referring general practitioner is an acceptable ordering provider under typical policy language and no specific restrictive provider specialty is documented in the patient information.,Yes,"UHC coverage criteria consider WES/WGS medically necessary for individuals (particularly children) with congenital anomalies or suspected genetic disorders when prior targeted testing is nondiagnostic. The patient has congenital anomaly since birth and prior targeted testing (FISH) was nondiagnostic, meeting a defined clinical indication.",No,"UHC policy generally requires prior appropriate targeted testing such as chromosomal microarray (CMA) as a first‑tier test for congenital anomalies; the record documents nondiagnostic FISH but does not document prior CMA, so required prior testing has not been completed.",No,"Family history relevant to multigene panels or specific hereditary cancer indications is not present (maternal aunt with pancreatic cancer is not directly relevant to a congenital anomaly evaluation), and there is no reported consanguinity—so relevant family history/consanguinity for WGS eligibility is not present.",Yes,"UHC requires documentation of pre-test genetic counseling and arrangements for post-test follow-up for WES/WGS. The patient has had multiple pre-test genetic counseling visits and post-test follow-up plans are in place, satisfying counseling requirements.",81425,CPT 81425 corresponds to whole genome sequencing (WGS) analysis and interpretation.,No,"Although the patient meets clinical indication for WGS and counseling/provider requirements are met, UHC requires completion of prior appropriate testing (e.g., chromosomal microarray) before coverage of WGS; CMA is not documented as completed, therefore WGS is not covered at this time.",1999,1951,3950
Case9349,baseline,without_policy,iter1,WES,The clinical note explicitly states the family was referred for whole exome sequencing (WES).,Not Specified,"BCBS_FEP WES policy is driven by clinical phenotype (e.g., multisystem congenital anomalies, developmental delay) rather than a strict numeric age cutoff; no explicit age restriction is specified and the patient is pediatric (5 y) but age alone is not a defined gating criterion in policy.",Not Specified,"BCBS_FEP policies typically require appropriate genetics involvement (documentation of counseling/consult) but do not universally mandate a specific ordering specialty; the record shows cardiology referral and documented pre‑test genetic counseling, so provider requirements are not explicitly unmet but the policy does not strictly specify an ordering‑provider specialty.",No,"BCBS_FEP WES coverage is limited to specific clinical indications (e.g., unexplained global developmental delay/intellectual disability, multiple congenital anomalies, progressive or complex multisystem disorders). This patient has an isolated congenital cardiac anomaly affecting a single organ system without multisystem involvement or neurodevelopmental disorder, so she does not meet the policy's defined medical‑necessity indications for WES.",No,"Policy generally expects prior appropriate targeted testing (e.g., relevant gene panel or chromosomal microarray when indicated) before WES for single‑system presentations. Only FISH (nondiagnostic) was done; no CMA or targeted cardiac/channelopathy panel is documented, so required prior testing has not been completed.",Not Specified,"While the patient has a relevant family history (paternal uncle with sudden unexplained death <35), BCBS_FEP WES policy does not set family history/consanguinity as a standalone eligibility requirement; family history may be supportive but it is not a clearly specified sufficient criterion for WES in isolation.",Yes,"BCBS_FEP expects documentation of pre‑test genetic counseling for complex genomic testing. The record documents pre‑test counseling with a genetic counselor and plans for post‑test follow‑up, satisfying counseling requirements.",81415,CPT 81415 corresponds to whole exome sequencing (proband or trio exome test reporting) and best maps to the requested WES.,No,"Applying BCBS_FEP coverage criteria: although counseling is documented and CPT mapping is 81415, the patient does not meet the policy's medical‑necessity indications for WES (isolated single‑organ congenital heart anomaly without multisystem involvement or developmental delay) and required prior targeted testing (e.g., CMA or relevant cardiac gene panel) is not documented; therefore WES is not covered in this case.",1990,2430,4420
Case1428,baseline,without_policy,iter1,WGS,The clinical note explicitly states whole genome sequencing (WGS) has been ordered.,Not Specified,"UHC WES/WGS coverage policy evaluates clinical indications (developmental delay, congenital anomalies, suspected genetic disorder) rather than specifying strict age cutoffs; the infant's age (3 weeks) does not conflict with UHC criteria.",Yes,"UHC typically requires that WES/WGS be ordered by or in consultation with a genetics specialist; the test is being ordered while the patient is being evaluated by a medical geneticist, satisfying provider requirements.",Yes,"UHC coverage criteria support WES/WGS for suspected genetic disorders such as congenital anomalies and unexplained neurodevelopmental disorders. The patient has Hirschsprung disease and a sibling with severe intellectual disability, meeting medical indication criteria.",No,"UHC policy expects appropriate prior testing (commonly chromosome microarray and fragile X testing) before WES/WGS for developmental/intellectual concerns. Fragile X testing was done and nondiagnostic, but no chromosomal microarray (CMA) is documented.",Yes,"UHC criteria consider family history of similar phenotypes relevant; there is a first‑degree sibling with severe intellectual disability, which is clinically relevant to WGS eligibility.",No,UHC requires documentation of pre‑test genetic counseling for WES/WGS. The record states there is no documented pre‑test genetic counseling.,81425,"CPT 81425 corresponds to whole genome sequencing (sequence analysis and interpretation), which matches the ordered test (WGS).",No,"Although the indication and ordering provider meet UHC criteria, required preconditions are lacking: no documented pre‑test genetic counseling and no documented prior chromosomal microarray. Per UHC policy these deficiencies would result in noncoverage until requirements are met.",1969,1755,3724
Case3359,baseline,without_policy,iter1,WES,The note explicitly states whole exome sequencing is being requested to evaluate for an underlying genetic etiology.,Yes,"UHC WES coverage is focused on pediatric patients with unexplained developmental delay/ hypotonia; the patient is a 4‑year‑old child, meeting pediatric age criteria for WES.",Yes,"Policies generally require ordering by or in coordination with an appropriate specialist; the test was ordered by a developmental pediatrician and pre‑test counseling was done by a genetic counselor, which meets provider/counseling requirements.",Yes,Clinical indications covered include unexplained global developmental delay/ongoing developmental concerns and significant hypotonia; the patient has these findings and a nondiagnostic prior CMA.,Not Answerable,"CMA was performed and nondiagnostic (a common required prior test and satisfied). However some payer rules also require condition‑specific prior testing (e.g., Fragile X testing in males); patient sex and whether any additional prior tests were completed are not provided.",Yes,"Family history is relevant to eligibility: there is a sibling with developmental delay, which supports a genetic evaluation and is noted in the clinical story.",Yes,Genetic counseling is required by UHC policy for WES; pre‑test counseling was completed with a genetic counselor on multiple occasions per the record.,81415,CPT 81415 corresponds to whole exome sequencing (sequence analysis and interpretation) and is the appropriate code for the requested test.,Yes,"Based on UHC coverage criteria applied to this case: pediatric patient with unexplained developmental delay and hypotonia, nondiagnostic CMA, appropriate specialist involvement and documented pre‑test genetic counseling — WES meets medical necessity and is covered. (Final coverage contingent on any additional payer‑required prior tests, e.g., Fragile X in males, if applicable.)",1993,2015,4008
Case9978,baseline,without_policy,iter1,WES,The patient record explicitly states 'whole exome sequencing (WES) at the request of the neurologist.',Not Specified,UHC coverage for WES is driven by clinical phenotype (childhood-onset neurodevelopmental/epileptic encephalopathy) rather than a strict age cutoff in this case; no payer-imposed absolute age exclusion is documented in the information provided.,Not Specified,"The case lists the ordering provider as a neurologist; the payer policy typically does not mandate a specific specialty beyond an appropriate clinician order, and no explicit ordering-provider restriction is provided in the patient information.",Yes,Patient has early-onset epileptic encephalopathy with onset before age 3 and persistent seizures into adulthood—this meets UHC criteria for WES when a suspected genetic cause of childhood-onset epilepsy exists and prior targeted testing has been nondiagnostic.,No,"UHC often requires prior appropriate testing (e.g., chromosomal microarray and/or targeted epilepsy gene panel or other targeted testing) before WES; only Fragile X testing (nondiagnostic) is documented and no CMA or prior targeted panel is documented.",Yes,The patient has a brother with an inborn error of metabolism; a family history of a related genetic disorder is relevant to eligibility under payer criteria for broader genomic testing.,Yes,"The record documents completion of pre-test counseling with a genetic counselor and plans for post-test follow-up, satisfying typical payer counseling requirements for WES.",81415,"CPT 81415 corresponds to clinical whole exome sequencing (WES), which is the test ordered.",No,"Although the patient meets clinical indication, required prior testing (e.g., chromosomal microarray and/or appropriate targeted gene testing per UHC policy) is not documented as completed; lacking required prior tests, the payer’s coverage criteria for WES would not be met.",1973,1900,3873
Case22,baseline,without_policy,iter1,BRCA1/2,Patient information explicitly states he is undergoing BRCA1/2 testing.,Not Specified,"BCBS_FEP BRCA testing policy is applied (payer-specific). There is no specific minimum/maximum age restriction cited for BRCA1/2 testing in this clinical context (adult testing is typical); the patient is 18 (an adult), and age-based limits are not specified.",Not Specified,BCBS_FEP coverage does not mandate a specific ordering specialty for BRCA1/2 in usual practice (physician or authorized provider order acceptable). The record lists a neurologist as the ordering provider; no payer-specific ordering-specialty restriction is specified in the applied policy.,Yes,"BCBS_FEP follows guideline-based indications: germline BRCA1/2 testing is indicated for men with metastatic high-risk prostate cancer and for tumors with intraductal/cribriform histology, particularly with a first‑degree relative (father) with similar metastatic prostate cancer. The patient meets these clinical criteria.",Not Specified,"There are no BCBS_FEP requirements that specific prior genetic tests (e.g., CMA) must be completed before BRCA1/2 testing; the provided prior CMA was nondiagnostic but not required for BRCA1/2 coverage.",Yes,"Family-history criteria are relevant for BRCA1/2 coverage; the patient has a first-degree relative (father) with metastatic high-risk prostate cancer with intraductal/cribriform features, which supports testing per payer criteria.",Yes,"BCBS_FEP commonly requires documented pre-test genetic counseling for germline testing; the patient completed pre-test counseling and plans post-test follow-up with a genetic counselor, satisfying counseling requirements.",81277,"Among the provided CPT choices, 81277 is the most appropriate gene-specific code representing BRCA1/BRCA2 testing relative to the other listed codes (81415/81425 correspond to exome/genome sequencing).",Yes,"Based on BCBS_FEP coverage applied to the patient's facts: metastatic high-risk prostate cancer with intraductal/cribriform histology, relevant family history, documented pre-test counseling, and no disqualifying age or prior-test requirements — BRCA1/2 testing is medically necessary and covered.",2011,1856,3867
Case5605,baseline,without_policy,iter1,WGS,The clinical note explicitly states the patient was referred for whole genome sequencing (WGS).,Not Specified,"BCBS_FEP WES/WGS policy does not impose a strict age cutoff in typical coverage criteria; the patient is 11 (pediatric), which is appropriate for testing, but the policy does not specify an age-based eligibility limit.",Not Specified,"BCBS_FEP policies generally require appropriate ordering clinicians and documentation of counseling, but do not universally restrict ordering to a single specialty in the published criteria. The record documents pre‑test counseling by a genetics specialist, but the ordering clinician is not explicitly restricted by the provided patient data.",Yes,BCBS_FEP WES/WGS coverage criteria include patients with major congenital anomalies or suspected genetic disorder after prior testing; this 11‑year‑old has a major congenital cardiac anomaly consistent with a covered indication.,Yes,"BCBS_FEP typically requires prior chromosomal microarray for congenital anomaly evaluation; the patient had a nondiagnostic CMA as documented, satisfying the prior test requirement.",Not Specified,"Family history/consanguinity is not a required element for routine WGS coverage in the applicable BCBS_FEP criteria, and the reported maternal aunt with pancreatic cancer is not relevant to the congenital cardiac indication.",Yes,"BCBS_FEP coverage for WES/WGS requires documentation of genetic counseling; the record states pre‑test counseling was completed with a genetic specialist, meeting that requirement.",81425,"Among the provided CPT options, 81425 corresponds to comprehensive clinical genomic sequencing (whole exome/whole genome level testing) and is the best match for the requested WGS.",Yes,"Under BCBS_FEP WES/WGS criteria the patient meets medical necessity: pediatric major congenital anomaly, nondiagnostic CMA, and documented pre‑test genetic counseling; therefore WGS is covered.",1969,2473,4442
Case19162,baseline,without_policy,iter1,WGS,The clinical note explicitly states testing was referred for whole genome sequencing (WGS).,Not Specified,"BCBS_FEP WES/WGS coverage criteria do not impose a strict age cutoff; WGS can be considered in neonates with suspected genetic disease, so no age-based exclusion is specified.",Yes,"BCBS_FEP typically requires ordering by an appropriate specialist (e.g., medical geneticist); the order was placed by a medical geneticist, satisfying provider requirements.",Yes,"The patient has unexplained, complex neonatal neurologic abnormalities (dystonia, ataxia, asymmetric weakness) with suspicion for an underlying genetic/metabolic cause — an indication consistent with BCBS_FEP criteria for WGS.",No,"BCBS_FEP coverage generally requires prior appropriate testing (e.g., chromosomal microarray and/or targeted tests) before WES/WGS unless exceptions apply; Fragile X testing was completed and nondiagnostic but no documentation of prior chromosomal microarray was provided.",Yes,Family history of an inborn error of metabolism in a sibling is documented and is relevant to eligibility under BCBS_FEP criteria supporting genomic testing.,Yes,"BCBS_FEP requires pre-test genetic counseling for WES/WGS; the record states pre-test counseling was completed and post-test follow-up is planned, meeting counseling requirements.",81425,The requested test is whole genome sequencing; CPT 81425 corresponds to genomic sequencing procedure — whole genome sequencing.,No,"Although clinical indication, ordering provider, counseling, and relevant family history support WGS, BCBS_FEP generally requires prior testing (notably chromosomal microarray) before WGS; no CMA is documented, so coverage criteria are not fully met.",1999,1933,3932
Case15834,baseline,without_policy,iter1,WES,Patient record explicitly states whole exome sequencing (WES) has been ordered.,Not Specified,UnitedHealthcare WES policy does not place specific age cutoffs for exome sequencing; age-based eligibility is not specified in the payer criteria.,Yes,"UHC typically requires ordering/consultation by a qualified genetics provider for WES; the record states pre-test counseling was completed with a genetic specialist, satisfying provider requirements.",No,"UHC coverage for WES generally requires documented moderate–severe developmental delay/intellectual disability, multiple congenital anomalies, or similar defined neurodevelopmental disorder. The infant has only early concern for ASD (no documented DD/ID or multiple congenital anomalies), so medical-necessity criteria are not met.",No,"UHC commonly requires prior targeted testing (e.g., Fragile X and chromosomal microarray) before WES for ASD/DD. Fragile X testing was nondiagnostic, but no prior chromosomal microarray is documented, so required prior testing is incomplete.",No,"Payer criteria that consider family history relevant generally require affected first‑degree relatives or a clear pattern; a maternal aunt with a congenital anomaly (second‑degree, nonspecific) does not meet those specified family‑history eligibility criteria.",Yes,"UHC requires documented pre‑test genetic counseling for WES; the record documents pre‑test counseling by a genetic specialist, meeting counseling requirements.",81415,CPT 81415 corresponds to exome sequencing (WES) with interpretation and report and best matches the requested test.,No,"Under UnitedHealthcare policy, coverage is not supported because the clinical indication (only early concern for ASD without documented DD/ID or multiple congenital anomalies) does not meet medical‑necessity criteria and a required prior test (chromosomal microarray) is not documented, despite Fragile X testing and genetic counseling being completed.",1974,1834,3808
Case13,baseline,without_policy,iter1,WES,The clinical note explicitly states the newborn 'has been referred for whole exome sequencing (WES)'.,Not Specified,BCBS_FEP WES coverage criteria do not impose a strict age cutoff for WES; the patient is a newborn and age-based exclusion is not described in the payer's criteria.,Not Specified,The provided information does not state any BCBS_FEP requirement that only a specific specialty must order WES; ordering-provider specialty requirements are not specified in the applicable coverage criteria.,Yes,"BCBS_FEP covers WES when there is unexplained multiple congenital anomalies or unexplained developmental disorders after prior testing; the newborn has multiple congenital anomalies not fitting a known syndrome and a sibling with unexplained developmental regression, meeting the clinical indication.",No,"BCBS_FEP generally requires prior genomic/structural testing (e.g., chromosomal microarray or equivalent) before WES for congenital anomalies/developmental delay; only a karyotype was performed and reported nondiagnostic, and no CMA/microarray result is documented, so required prior testing has not been completed.",Yes,Family history is relevant per BCBS_FEP criteria (affected sibling with unexplained developmental regression); the patient has a positive family history that supports WES consideration.,Yes,"BCBS_FEP requires pre-test genetic counseling for WES; the record states pre-test genetic counseling was completed and post-test follow-up is planned, satisfying counseling requirements.",81415,CPT 81415 corresponds to clinical exome sequencing (WES) with interpretation/reporting and is the appropriate code for the requested whole exome sequencing.,No,"Although the clinical indications, family history, and counseling meet BCBS_FEP criteria for WES, required prior diagnostic testing (notably chromosomal microarray) is not documented. Per BCBS_FEP rules, lack of required prior testing makes the request not covered at this time.",1976,1846,3822
Case16487,baseline,without_policy,iter1,WES,The clinical note explicitly states whole exome sequencing (WES) has been ordered.,Not Specified,UnitedHealthcare WES coverage criteria are indication-driven rather than strictly age-limited; no age restriction is specified in the provided clinical context and the newborn status does not conflict with typical UHC policies for diagnostic WES in critically/clinically affected infants.,Not Specified,"UHC policies generally require an appropriate ordering clinician but do not uniformly mandate a specific specialty for WES (orders from treating specialists are typically acceptable). The record shows an oncologist ordered testing, which would usually be an acceptable treating specialist; the policy does not strictly specify specialty in this case.",Yes,"Per UHC diagnostic WES criteria, WES is indicated for unexplained, potentially genetic conditions after prior focused testing is nondiagnostic. The infant has recurrent high-risk BRUE events with nondiagnostic FISH testing, meeting a criterion of an unexplained, recurrent neonatal event where WES is clinically indicated.",Not Specified,"UHC may require prior targeted testing depending on the clinical presentation (e.g., gene panel, CMA) but requirements vary by indication. The chart documents nondiagnostic FISH only; whether additional specific prior tests (e.g., CMA or specific panels) were required by policy for this indication is not specified in the provided information.",Yes,"Family history is relevant to eligibility under UHC criteria when present; this infant has a maternal aunt with a severe immunologic/hematologic disorder, which supports a possible hereditary etiology and is relevant to the decision to pursue WES.",Yes,"UHC commonly requires documentation of pre-test genetic counseling for complex genomic testing. The record states pre-test counseling was completed with plans for post-test genetic follow-up, satisfying counseling requirements.",81415,"CPT 81415 corresponds to clinical exome sequencing (WES), which matches the ordered test.",Yes,"Under UHC coverage principles for diagnostic WES, the infant has an appropriate clinical indication (recurrent unexplained neonatal BRUE), prior targeted testing was nondiagnostic (FISH), pre-test counseling completed, and supportive family history—together meeting coverage criteria for WES.",1985,1767,3752
Case3677,baseline,without_policy,iter1,BRCA1/2,Patient is explicitly stated to be 'undergoing BRCA1/2 testing.',Yes,"UHC BRCA coverage policies include age-based criteria (e.g., breast cancer diagnosed ≤50 years); the patient is 46, which meets typical age-based eligibility thresholds for BRCA testing under UHC criteria.",Not Specified,UHC BRCA policies generally do not restrict ordering to a narrow provider specialty in the documentation provided here; the record shows a nurse practitioner referral but the payer policy does not specify an ordering-provider exclusion in this context.,Yes,Clinical indications in UHC BRCA criteria include a personal history of breast cancer plus a family history of BRCA-associated cancers (mother with pancreatic cancer and multiple affected maternal relatives). The patient meets these medical-necessity criteria.,Not Specified,UHC BRCA coverage does not require prior diagnostic testing (other than documenting family history or known familial variant) in this scenario; the prior CMA being nondiagnostic is noted but not a required prior test for BRCA.,Yes,UHC criteria consider family history of pancreatic cancer and multiple affected first-/second-degree relatives as relevant for BRCA testing; the patient has a mother with pancreatic cancer and at least two additional affected maternal relatives.,Yes,"UHC BRCA testing policies require genetic counseling (pre- and/or post-test) or documentation thereof. The patient completed pre-test genetic counseling and plans post-test follow-up, meeting counseling requirements.",Not Specified,"The typical CPT codes for BRCA1/BRCA2 full-gene testing (e.g., gene-specific codes) are not among the listed options; therefore no provided code clearly matches the ordered BRCA1/2 test.",Yes,"Applying UHC BRCA coverage criteria: the patient has a personal history of breast cancer, is age 46 (within common age-based thresholds), has a strong family history including pancreatic cancer, and has completed pre-test genetic counseling — together these satisfy UHC medical-necessity and counseling requirements for coverage.",1997,3018,5015
Case3474,baseline,without_policy,iter1,WGS,The chart explicitly states whole genome sequencing (WGS) is being ordered.,Yes,Patient is a 5‑year‑old child; UHC pediatric WES/WGS age criteria are met for pediatric patients when clinically indicated.,Yes,"Ordering clinician is a medical geneticist; UHC requires an appropriate specialist (e.g., geneticist) for WGS orders and that requirement is satisfied.",Yes,Clinical indications present (congenital choanal atresia/structural birth defect and a sibling with developmental delay) meet UHC clinical criteria for evaluation for an underlying genetic etiology.,No,UHC coverage typically requires prior chromosomal microarray (or other specified prior testing) before WGS; only a nondiagnostic karyotype is documented and CMA is not documented as completed.,Yes,"There is a relevant family history: an older sibling with developmental delay, which is a specified supportive criterion in coverage guidance.",Yes,"Pre‑test genetic counseling has been completed and post‑test follow‑up planned, meeting UHC counseling requirements for clinical WGS.",81425,81425 is the CPT code that corresponds to clinical whole genome sequencing (germline) billed for WGS.,No,"Although age, provider, indications, family history, and counseling meet UHC criteria, required prior testing (chromosomal microarray) is not documented; per UHC policy lack of required prior testing typically results in noncoverage pending completion of those tests.",1982,1306,3288
Case15938,baseline,without_policy,iter1,WGS,The case explicitly states 'whole-genome sequencing (WGS) is being considered.',Not Specified,"UHC WGS/WES policies do not impose a strict age cutoff; age-based eligibility is not specifically restricted for WGS, so no explicit age criterion applies beyond clinical indication.",Not Specified,"UHC policies generally do not mandate a single specific ordering provider specialty for WGS (orders commonly come from treating specialists), and no provider restriction is documented in the patient facts.",Yes,Patient is a neonate with unexplained conjugated hyperbilirubinemia (possible genetic/metabolic cholestasis) plus a sibling with unexplained developmental regression and prior nondiagnostic karyotype — these fulfill UHC clinical indications for genomic sequencing to evaluate a suspected monogenic/metabolic disorder.,No,"UHC typically requires prior appropriate testing (e.g., chromosomal microarray or other targeted testing) before WGS unless rapid/acute NICU criteria are met. Only a nondiagnostic karyotype is documented and no CMA or other required prior testing is recorded.",Yes,Family history is relevant and supportive: a sibling with unexplained developmental regression meets family-history criteria used by UHC to justify genomic sequencing.,No,"UHC policies expect documentation of pre-test genetic counseling/consent for genomic sequencing. The record states no pretest genetic counseling is documented, so counseling requirements are not met.",81425,"CPT 81425 corresponds to genomic-scale sequencing (whole exome/whole genome) interpretation/reporting, which best matches the requested WGS.",No,"Although clinical indication is present, coverage would be denied under UHC criteria because required prior testing (e.g., CMA or other targeted testing) is not documented and pretest genetic counseling is not documented; rapid/critical-care WGS criteria are not documented to waive prior-test requirements.",1987,2280,4267
Case4067,baseline,without_policy,iter1,WES,The clinical note explicitly states whole exome sequencing (WES) has been ordered.,Not Specified,UHC WES policies do not impose strict upper/lower age cutoffs for diagnostic WES in patients with suspected genetic causes of developmental disorders; thus age-based exclusion is not specified and a 5-year-old is within typical covered pediatric indications.,Not Specified,The record identifies a referring developmental pediatrician but UHC WES policy generally does not mandate a single specific ordering specialty in all cases (orders from qualified specialists are acceptable); no explicit ordering-provider restriction is documented in the patient data.,Yes,UHC covers WES for unexplained neurodevelopmental disorders/significant hypotonia when a genetic etiology is suspected; the patient has significant hypotonia/developmental concerns meeting a covered clinical indication.,No,"UHC coverage criteria for WES typically require prior higher-resolution cytogenomic testing (chromosomal microarray) for developmental delay/hypotonia. The patient had a chromosomal karyotype (nondiagnostic) but no CMA documented, so required prior testing is not completed.",Yes,"The family history includes sudden unexplained death in a paternal uncle <35, which is relevant and supportive of a heritable disorder per UHC criteria (family history noted enhances clinical justification).",No,UHC typically expects documentation of pre-test genetic counseling/consent for WES; no genetic counseling or consent information is provided in the patient data.,81415,The requested test is proband whole exome sequencing; CPT code 81415 corresponds to clinical diagnostic whole exome sequencing for a single individual.,No,"Although the patient meets medical indication (developmental hypotonia), UHC requires prior cytogenomic testing (chromosomal microarray) and documentation of genetic counseling before WES authorization. Required prior testing and counseling are not documented, so coverage is not supported at this time.",1970,1524,3494
Case11514,baseline,without_policy,iter1,WES,The case text explicitly states 'whole exome sequencing (WES) has been requested.',Not Specified,UHC WES coverage is driven by clinical indication rather than strict age cutoffs; no age-based exclusion is specified and a 10‑year‑old is an appropriate pediatric candidate.,Not Specified,"UHC medical policy requires an appropriate ordering clinician but does not mandate a specific specialty (e.g., only geneticist); the record lists an oncologist as the ordering provider, which is not explicitly disallowed by policy.",Yes,"Clinical criteria for WES are met: unexplained early-onset cholestatic liver disease with suspicion of an inherited/metabolic disorder and nondiagnostic prior targeted testing (CMA), which fits UHC indications for WES to evaluate a suspected monogenic disorder.",Yes,"UHC commonly requires prior standard testing (e.g., CMA) before WES in many pediatric genetic evaluations; the patient had a nondiagnostic chromosomal microarray, satisfying that prior test requirement.",Yes,"Family history is relevant: an inborn error of metabolism in a cousin increases pretest probability of an inherited metabolic disorder, which is a listed supporting criterion for WES.",No,"UHC policies expect documentation of pre‑test genetic counseling/consent for genomic testing; the chart states there is no documentation of pre‑test genetic counseling, so counseling requirements are not met.",81415,CPT 81415 corresponds to clinical whole exome sequencing (proband or single‑sample exome) which matches the requested WES.,Yes,"Clinical indications (early‑onset cholestasis, suspected metabolic/genetic etiology, nondiagnostic CMA, relevant family history) meet UHC medical necessity criteria for WES. The only policy deficiency is absent documented pre‑test counseling, which may require remediation but does not negate medical necessity for coverage if counseling is documented or completed per payer process.",2007,1654,3661
Case11981,baseline,without_policy,iter1,WGS,The note explicitly states whole genome sequencing (WGS) is being requested.,Not Specified,UHC WES/WGS policies do not impose a strict age cutoff; the 9‑year‑old pediatric age is within usual policy scope but no explicit age-based restriction is specified in the policy.,Yes,"UHC requires documentation of genetics evaluation and/or ordering by an appropriate specialist; the record documents pre‑test discussion with a genetic specialist, satisfying ordering/provider requirements.",Yes,"UHC covers WGS for unexplained neurodevelopmental disorders/concerns present since infancy (abnormal tone, ongoing motor and developmental concerns), so the clinical presentation meets medical indication criteria.",No,"UHC typically requires prior targeted testing (eg, chromosomal microarray and Fragile X where appropriate) before WES/WGS; Fragile X was nondiagnostic but no documentation of prior chromosomal microarray (CMA) is provided.",Not Specified,UHC policies do not require a specific familial history for WGS (family history can be supportive but is not a formal required criterion); the maternal uncle's immunologic disorder is noted but family history requirements are not specified as a gating criterion.,Yes,"Genetic counseling/pre‑test discussion is a UHC requirement for WES/WGS; the chart documents pre‑test discussion with a genetic specialist, meeting counseling requirements.",81425,CPT 81425 corresponds to clinical whole genome sequencing (WGS) analysis and reporting; this best matches the requested test.,No,"Although the indication, counseling, and specialist involvement meet UHC criteria, required prior testing (notably chromosomal microarray) is not documented; per UHC coverage rules WGS is not covered until prior required testing is completed.",1992,1940,3932
Case7682,baseline,without_policy,iter1,WES,The clinical note explicitly states whole exome sequencing (WES) is being requested to identify a genetic cause for multiple congenital abnormalities.,Not Specified,"UnitedHealthcare WES coverage criteria do not impose a strict age cutoff for WES; pediatric age alone does not bar eligibility, so no age-based exclusion applies to this 9‑year‑old.",Yes,"UHC typically requires an appropriate ordering provider and/or documented genetics involvement for WES. The record documents referral by a developmental pediatrician and pre‑test counseling with a genetic specialist, satisfying provider/counseling requirements.",Yes,"UHC policy supports WES for unexplained multi‑system congenital anomalies and neurodevelopmental disorders after prior testing; this child has multiple congenital anomalies affecting different organ systems and developmental concerns, meeting medical indication criteria.",No,"UHC generally requires prior appropriate first‑tier testing (e.g., chromosomal microarray and other indicated targeted tests) before WES. The record notes a nondiagnostic karyotype but does not document completion of chromosomal microarray or other required prior testing.",Yes,Family history is relevant under UHC criteria (a sibling with developmental delay supports genetic evaluation). The record documents a sibling with developmental delay.,Yes,UHC requires documentation of pre‑test genetic counseling for WES. The record states pre‑test counseling was completed with a genetic specialist and plans for post‑test follow‑up.,81415,The CPT code corresponding to diagnostic whole exome sequencing is 81415 (sequencing of the exome).,No,"Although clinical indication, provider involvement, counseling, and family history meet UHC criteria, required prior testing (notably chromosomal microarray/other first‑tier tests) is not documented. Per UHC policy WES coverage is contingent on prior appropriate testing being nondiagnostic, so coverage is not supported until those prior tests are completed.",1973,1392,3365
Case3494,baseline,without_policy,iter1,WES,The case statement explicitly says whole exome sequencing (WES) is being requested for diagnostic clarification.,Not Specified,Cigna WES policy does not impose a strict age cutoff for testing; eligibility is driven by clinical presentation rather than a specific patient age.,Not Specified,Cigna policies require an appropriate ordering clinician but do not universally restrict ordering to a single specialty in all situations; the record shows referral for genetic evaluation but does not indicate a disqualifying ordering-provider issue.,Yes,"Cigna considers WES medically indicated for individuals with multiple congenital anomalies or suspected complex neurodevelopmental genetic disorders. The infant has a congenital abnormality with concern for evolving complex neurodevelopmental disorder and a sibling with dysmorphic features, meeting clinical indication criteria.",No,"Cigna typically expects first‑line testing (e.g., chromosomal microarray and other indicated targeted tests) to have been considered/completed for congenital anomaly/developmental‑delay presentations prior to WES unless clinically justified. This infant has had no prior genetic testing documented, so required prior testing has not been completed.",Yes,"There is a relevant family history (a sibling with dysmorphic features), which Cigna considers supportive for proceeding with comprehensive genetic testing.",No,"Cigna requires that genetic testing be accompanied by appropriate genetic counseling (pre‑ and/or post‑test). The family declined genetic counseling, so counseling requirements are not met.",81415,The test requested is whole exome sequencing; CPT 81415 corresponds to clinical exome sequencing.,No,"Although the clinical indication and family history support WES, required prior testing (e.g., chromosomal microarray/other first‑line tests) has not been completed and the family declined required genetic counseling; under Cigna coverage rules these unmet requirements support denial of coverage as submitted.",1975,2081,4056
Case7014,baseline,without_policy,iter1,WGS,Clinical note explicitly states whole genome sequencing (WGS) is being requested.,Yes,UHC sequencing policy is focused on pediatric patients with congenital anomalies; the patient is a 7‑week infant (meets pediatric age criteria).,Yes,"UHC requires involvement/oversight by a genetics provider or specialist for clinical genomic sequencing; pre‑test genetic counseling was completed with a genetic specialist and testing will be reviewed with genetics and neurology, satisfying ordering/provider requirements.",Yes,"UHC clinical indications include infants/children with multiple congenital anomalies or unexplained syndromic presentations; this infant has multiple congenital anomalies that do not fit a defined syndrome, which meets the medical indication criterion.",No,UHC sequencing policies generally require prior appropriate cytogenetic testing such as chromosomal microarray (CMA) before WGS; only a nondiagnostic karyotype is documented and CMA is not reported as completed.,Yes,Family history is relevant per UHC criteria when present; a maternal aunt with a congenital anomaly is documented and is potentially supportive for genetic evaluation.,Yes,UHC requires pre‑test genetic counseling for clinical genomic sequencing; pre‑test counseling was completed with a genetic specialist as documented.,81425,81425 corresponds to clinical whole genome sequencing and matches the WGS test requested.,No,"Although age, clinical indication, genetics involvement, counseling, and family history meet UHC criteria, required prior testing (notably CMA) is not documented; per UHC coverage rules WGS would not be approved until required prior testing is completed or documented exceptions provided.",1983,1584,3567
Case13517,baseline,without_policy,iter1,WES,"The case statement explicitly says ""whole exome sequencing (WES) was ordered.""",Yes,"UnitedHealthcare WES coverage is age-qualified for pediatric-onset presentations; the patient is 16 years old, which meets pediatric age-based eligibility for WES.",Not Specified,"UHC policies typically require an appropriate ordering clinician and documentation of counseling but do not mandate a single specific specialty for ordering; the record shows a developmental pediatrician referral and genetic counselor involvement, which satisfy usual practice but a strict provider-specialty requirement is not specified in the policy text.",Yes,Coverage criteria support WES when a genetic etiology is suspected for unexplained clinical findings (including suspected inborn errors of metabolism or unexplained conjugated hyperbilirubinemia) and/or when an affected sibling suggests an inherited disorder; this patient has conjugated hyperbilirubinemia and a sibling with lab abnormalities suggestive of an IEM.,Not Specified,"UHC WES policies may request that targeted testing be performed when a specific single-gene test is strongly indicated, but no specific required prior tests for this clinical presentation are documented in the provided information; only Fragile X (nondiagnostic) is noted.",Yes,"The patient has a relevant family history: a sibling with laboratory abnormalities suggestive of an inborn error of metabolism, which supports genetic testing per coverage criteria.",Yes,"UHC typically requires documentation of pre-test genetic counseling for WES; the file states pre-test counseling was completed with a genetic counselor and post-test counseling is planned, meeting that requirement.",81415,CPT 81415 corresponds to clinical whole exome sequencing (proband-only or exome sequence analysis) and is the CPT most consistent with the requested WES.,Yes,"Based on UHC coverage criteria for pediatric patients with suspected genetic disorders (age met), presence of a relevant affected sibling, documented pre-test genetic counseling, and an appropriate clinical indication (unexplained conjugated hyperbilirubinemia suspicious for an IEM), WES meets coverage criteria.",1991,1871,3862
Case14127,baseline,without_policy,iter1,WES,The case text explicitly states 'whole exome sequencing (WES) is being pursued.',Not Specified,UHC WES coverage criteria do not impose a specific age cutoff for exome sequencing for unexplained neurodevelopmental disorders; age (17) is not a limiting factor per typical policy.,Yes,"UHC policies require tests to be ordered/coordinated by an appropriate provider (medical geneticist or other qualified clinician). The medical geneticist is coordinating testing, which satisfies ordering-provider requirements.",Yes,"UHC indicates WES is clinically indicated for unexplained global developmental delay/intellectual disability and related neurodevelopmental presentations; the patient has lifelong GDD/cognitive and adaptive deficits, meeting the medical indication.",No,"UHC typically requires prior diagnostic chromosomal microarray testing (and in some cases Fragile X testing for males) before WES for GDD/ID. The record only documents nondiagnostic FISH (not equivalent to CMA) and no CMA/Fragile X results, so required prior testing has not been completed.",Yes,"There is a relevant family history: a sibling with epileptic encephalopathy with onset before age three, which is pertinent to genetic evaluation and included in coverage considerations.",Yes,"UHC expects documentation of genetic counseling for WES. The patient had pre-test genetic counseling and will return for post-test counseling, meeting counseling requirements.",81415,CPT 81415 corresponds to clinical exome sequencing (WES) and is the appropriate code for the requested test.,No,"Although clinical indication, ordering provider, and counseling requirements are met, UHC coverage requires prior diagnostic CMA (and where applicable Fragile X) before approving WES for GDD/ID. No CMA/Fragile X results are documented, so coverage would be denied until required prior testing is completed.",2003,1637,3640
Case15820,baseline,without_policy,iter1,CMA,The note explicitly states a chromosomal microarray (CMA) has been ordered to evaluate for copy number variants for developmental delay/intellectual disability.,Not Specified,Cigna's CMA coverage is driven by clinical indication (unexplained developmental delay/ID) rather than a strict age cutoff; the record shows a 31‑year‑old but no payer age restriction is specified in policy.,Yes,Ordering provider is neurology (a treating physician). Cigna allows ordering by the treating physician/specialist for diagnostic CMA; no specialty restriction preventing a neurologist was identified.,Yes,"Cigna covers CMA as a first‑tier test for individuals with unexplained developmental delay/intellectual disability — the patient has developmental delay and intellectual disability without a specific syndrome, meeting the medical indication.",Not Specified,"Cigna considers CMA a first‑line test for unexplained developmental delay/ID; there are no required prior genetic tests listed and the patient has no prior testing, which is acceptable per policy.",Not Specified,"Family history of early breast cancer (mother <50) is relevant for hereditary cancer testing (e.g., BRCA) but is not a specified eligibility criterion for CMA; Cigna's CMA policy does not require family history or consanguinity.",Not Specified,"While genetic counseling is recommended and the patient completed pre‑test counseling, Cigna's CMA coverage criteria do not mandate a specific documented counseling workflow as a strict eligibility requirement in the policy language provided.",81228,"CPT 81228 corresponds to chromosomal microarray (CMA) testing (copy number variant analysis), which best fits the ordered test.",Yes,"Per Cigna policy, CMA is covered for unexplained developmental delay/intellectual disability. The patient meets the clinical indication, has no disqualifying age or prior‑test requirements, the ordering physician is appropriate, and counseling was performed.",1984,1711,3695
Case13675,baseline,without_policy,iter1,WGS,The note explicitly states whole genome sequencing (WGS) is being pursued for diagnostic clarification.,Yes,UnitedHealthcare WES/WGS coverage policies specify pediatric patients with early-onset congenital anomalies or suspected monogenic disorders are eligible; an 8‑week‑old infant with congenital hearing/visual impairment meets pediatric age criteria.,Yes,"UHC policies require an appropriate ordering clinician (physician or qualified specialist) – the test was ordered by a neonatologist, which meets ordering provider requirements.",Yes,UHC generally covers WGS when used to evaluate unexplained congenital anomalies or early-onset multisystem findings; significant congenital hearing and/or visual impairment in early infancy is a recognized medical indication.,No,"UHC commonly requires prior appropriate targeted testing (e.g., chromosomal microarray) or documentation that prior standard testing was nondiagnostic; only FISH (nondiagnostic) is documented and no CMA or other recommended prior testing is shown.",Yes,"Family history of a father with long QT syndrome is documented and is potentially relevant to interpretation of cardiac-related findings, which UHC considers supportive evidence for broader genomic testing.",No,UHC typically requires documentation of pre-test genetic counseling for WGS/WES; the record states there is no documentation of pre-test genetic counseling.,81425,"CPT 81425 corresponds to whole genome sequencing (WGS) interpretation and report, matching the explicitly requested test.",No,"Although age, provider, and clinical indication are met, required pre-test documentation is incomplete per UHC policy (no documented pre-test genetic counseling and no documented prior chromosomal microarray/required prior testing), so coverage criteria are not fully satisfied.",1994,1602,3596
Case2162,baseline,without_policy,iter1,WGS,The patient information explicitly states the infant was referred for whole genome sequencing (WGS).,Not Specified,BCBS_FEP coverage for WGS/WES typically focuses on clinical indications rather than strict age cutoffs; no age-based exclusion or requirement is specified for an infant in the provided policy context.,Not Specified,"The BCBS_FEP WGS/WES coverage criteria emphasize clinical indications and pre-test counseling; the information provided does not indicate a payer requirement that a specific specialty (e.g., clinical geneticist) must place the order.",Yes,"Per BCBS_FEP criteria, WGS/WES is medically indicated for patients with multiple congenital anomalies/multi-system involvement or suspected monogenic disorder; this infant has multiple congenital anomalies affecting multiple organ systems identified at birth.",No,"BCBS_FEP policies for WGS/WES commonly require prior standard genetic testing (e.g., chromosomal microarray) to be nondiagnostic before WGS in non‑critically ill patients; only Fragile X testing is documented (nondiagnostic), but no chromosomal microarray (CMA) result is provided.",Not Specified,"While family history (an older sibling with ASD) is clinically relevant and supportive, BCBS_FEP WGS/WES coverage criteria do not mandate a specific family-history pattern as a general prerequisite, and the policy does not specify consanguinity/family-history requirements for this indication.",Yes,"BCBS_FEP requires documentation of pre‑test genetic counseling for WGS/WES; the record states pre-test genetic counseling was completed and post-test follow-up is planned, satisfying this requirement.",81425,CPT 81425 corresponds to whole genome sequencing procedures and is the code that best maps to the requested WGS.,No,"Although the infant meets clinical indication and genetic counseling requirements, BCBS_FEP generally requires prior standard genetic testing (notably chromosomal microarray) to be nondiagnostic before approving WGS in non‑critically ill infants; no CMA result is documented, so coverage criteria are not fully met.",1965,2451,4416
Case7376,baseline,without_policy,iter1,WES,The case states whole exome sequencing (WES) has been ordered for diagnostic clarification.,Not Specified,UHC WES medical policy is based on diagnostic indications rather than strict age cutoffs; no age-based exclusion is specified and the policy can apply to adults.,Yes,"Policy requires appropriate ordering/consultation and pre‑test genetic counseling; the patient was referred by a neurologist and pre‑test counseling was completed with a genetic specialist, satisfying provider/counseling requirements.",Yes,UHC criteria support WES for an unexplained major structural/functional abnormality involving at least one organ system after prior testing is nondiagnostic; the patient has an unexplained major abnormality meeting that indication.,No,"UHC typically requires prior appropriate genetic testing (eg, chromosomal microarray/karyotype and/or targeted testing) to be nondiagnostic before WES; only prior FISH (a targeted test) was done and no CMA/karyotype is documented.",Yes,"The patient reports a sister with triple‑negative breast cancer, which is a family history suggestive of a heritable cancer predisposition relevant to genetic evaluation.",Yes,"Pre‑test counseling was completed with a genetic specialist, which meets UHC requirements for genetic counseling prior to WES.",81415,CPT 81415 corresponds to clinical exome sequencing (WES) and is the appropriate code for the requested test.,No,"Although indications, provider involvement, counseling, and family history meet UHC criteria, required prior testing (eg, chromosomal microarray/karyotype or other recommended prior genetic tests) is not documented (only nondiagnostic FISH), so coverage would not be supported until prior testing requirements are met or documented as not applicable.",1983,2322,4305
Case11124,baseline,without_policy,iter1,WES,The clinical note explicitly states whole-exome sequencing (WES) has been ordered.,Yes,UnitedHealthcare WES coverage is generally limited to pediatric patients with unexplained developmental delay/ID or congenital anomalies; the patient is an infant and therefore meets age-based (pediatric) eligibility.,Not Specified,"The provided information says the referral/ordering was via an oncologist, but UHC policy language does not universally mandate a specific ordering specialty for WES in every instance; no explicit ordering-provider restriction is documented in the patient information.",Yes,"UHC policy supports WES for unexplained developmental delay/early intellectual disability or suspected genetic etiology; the infant presents with developmental delay and a sibling with childhood hearing impairment, meeting medical indication criteria.",No,"UHC generally requires first‑tier testing (chromosomal microarray) prior to WES for unexplained developmental delay; the record notes prior FISH was nondiagnostic but does not document a prior CMA, so required prior testing has not been completed.",Yes,"Family history is positive for an older sibling with significant childhood hearing impairment, which is relevant and supportive of a hereditary etiology per UHC criteria for comprehensive exomic testing.",Yes,"UHC requires genetic counseling associated with WES; the record documents pre-test counseling was completed and post-test counseling is planned, satisfying counseling requirements.",81415,CPT 81415 corresponds to exome sequencing (WES) for a proband and is the appropriate code for the ordered WES.,No,"Although age, clinical indication, family history, and counseling meet UHC criteria, UHC's coverage requires prior chromosomal microarray (or equivalent first‑tier testing) before WES for developmental delay; no CMA is documented, so WES is not covered at this time.",1978,1499,3477
Case8051,baseline,without_policy,iter1,WES,The clinical note explicitly states whole exome sequencing (WES) is being ordered to evaluate the infant with a major congenital cardiac anomaly.,Not Specified,"BCBS_FEP WES coverage criteria are not typically age‑restricted; policies apply to pediatric and adult patients. No specific age cutoff is stated in the provided payer-context, so age-based criteria are not specified.",Not Specified,"The provided payer context does not explicitly state a required ordering specialty. Although some policies prefer genetics involvement, the chart documents that pre‑test genetic counseling was completed, and there is no explicit BCBS_FEP ordering‑provider restriction given in the patient information.",Yes,"BCBS_FEP WES medical‑necessity criteria include unexplained congenital anomalies or suspected syndromic conditions; this infant has a major congenital cardiac anomaly with concern for syndromic etiology, meeting a clinical indication for WES.",No,"BCBS_FEP often requires prior relevant genomic tests (e.g., chromosomal microarray) before WES for congenital anomalies. The record documents prior FISH was nondiagnostic but does not document that CMA was completed, so required prior testing has not been completed.",Yes,"Family history relevant to genetic evaluation is present: the mother has short stature raising concern for a growth‑related genetic condition, which is pertinent to syndromic assessment and WES eligibility.",Yes,"Pre‑test genetic counseling was completed by the family and follow‑up is planned, meeting BCBS_FEP counseling requirements that accompany complex genomic testing in many policies.",81415,CPT 81415 corresponds to clinical exome sequencing (WES) and is the appropriate code for the requested test.,No,"Although clinical indication, family history, and genetic counseling are documented, BCBS_FEP criteria typically require prior genomic testing (e.g., chromosomal microarray) before WES for congenital anomalies; only FISH (nondiagnostic) was done. Because required prior testing was not completed, the request does not meet the payer's coverage prerequisites.",1987,1868,3855
Case19905,baseline,without_policy,iter1,WES,The clinical note explicitly states the patient is being considered for whole exome sequencing (WES).,Not Specified,UHC WES coverage criteria do not impose a strict age cutoff for WES; the policy is based on clinical indication rather than a specific age limit.,Not Specified,"UHC generally requires an appropriate ordering clinician, but the policy language typically allows ordering by the treating physician (e.g., pediatrician, geneticist). The referral is from a developmental pediatrician which is appropriate, and specific restrictive provider-type requirements are not specified in the provided information.",Yes,"UHC covers WES for individuals with multiple congenital anomalies and unexplained developmental delay/ID after appropriate prior testing; this 3‑year‑old has multiple congenital anomalies and was referred by a developmental pediatrician, meeting the clinical indication requirement.",No,"UHC policy requires prior appropriate cytogenomic testing (chromosomal microarray) to be nondiagnostic before WES. The patient had a nondiagnostic karyotype but no CMA documented, so the required prior test (CMA) has not been completed.",Not Specified,"While a family history can be supportive, UHC WES criteria are primarily driven by the proband's phenotype (e.g., developmental delay, multiple anomalies). The policy does not make the presence of family history/consanguinity a strict requirement in this context; the mother’s long QT is noted but not specified as a coverage criterion for WES here.",No,"UHC typically requires documentation of pre‑test genetic counseling or informed consent for WES. The record states no genetic counseling has been conducted to date, so counseling requirements are not met.",81415,"CPT 81415 corresponds to whole exome sequencing (proband only), which best matches the requested WES.",No,"Although the patient meets the clinical indication for WES (multiple congenital anomalies), UHC coverage requires prior chromosomal microarray to be nondiagnostic and documentation of pre‑test genetic counseling. CMA has not been documented and counseling not completed, so coverage criteria are not met.",1955,1879,3834
Case10850,baseline,without_policy,iter1,WGS,The clinical note explicitly states whole genome sequencing (WGS) has been ordered.,Not Specified,UHC WGS/WES coverage criteria do not impose a strict age cutoff for pediatric testing; the patient is 13 but the policy does not specify an age restriction relevant to eligibility.,Not Specified,"UHC policy does not explicitly restrict ordering to a narrow provider type in this scenario; the test is ordered by a developmental pediatrician and pre-test genetic counseling is documented, with no payer-specific ordering-provider disqualification noted in the record.",No,"UHC criteria define coverage for WGS/WES for unexplained global developmental delay/intellectual disability only after standard first‑tier testing (eg, chromosomal microarray and other indicated targeted tests) are nondiagnostic; the patient has global developmental delay but has only had nondiagnostic FISH (not CMA), so specific medical indication requirements are not met.",No,UHC requires prior diagnostic testing such as chromosomal microarray (and other appropriate targeted tests) before WGS; the record shows only nondiagnostic FISH and does not document completion of CMA or other required prior tests.,Yes,The patient has a relevant family history (an aunt with dysmorphic features); UHC guidance considers family history of similar phenotypes relevant to genetic evaluation.,Yes,"UHC policies require pre‑test genetic counseling for complex genomic testing; the family completed pre‑test counseling and plans for post‑test follow-up, meeting counseling requirements.",81425,"CPT code 81425 corresponds to clinical whole genome sequencing (WGS), which matches the ordered test.",No,"Although the clinical presentation (global developmental delay), positive family history, and documented pre‑test counseling support evaluation, UHC coverage requires completion of first‑tier testing (eg, chromosomal microarray) prior to WGS; because required prior testing has not been completed, WGS is not covered per policy.",1975,2102,4077
Case19321,baseline,without_policy,iter1,WES,The clinical note explicitly states 'whole exome sequencing (WES) is being pursued' to investigate a possible genetic etiology for a complex neurodevelopmental disorder.,Yes,"UHC coverage for WES specifies pediatric eligibility for unexplained neurodevelopmental disorders; the patient is 1 year old, meeting the pediatric age-based criterion.",Yes,"UHC typically requires ordering by a specialist or provider experienced in genetics (e.g., geneticist, neurologist); the test was referred/ordered by a neurologist, satisfying provider requirements.",Yes,UHC medical necessity criteria support WES for pediatric patients with complex neurodevelopmental disorder/autism features when a genetic etiology is suspected; the patient has these indications.,Yes,UHC generally requires prior chromosomal microarray (CMA) for unexplained developmental delay/ASD before WES; the record documents a nondiagnostic CMA was completed.,Yes,Family history relevant to genetic evaluation is considered supportive by UHC; a maternal aunt with multiple congenital anomalies is documented and is relevant to eligibility.,Yes,"UHC requires pre-test genetic counseling for WES; the record states pre-test genetic counseling was completed and post-test follow-up is planned, meeting counseling requirements.",81415,CPT 81415 corresponds to whole exome sequencing (proband-level) and best matches the requested WES.,Yes,"All applicable UHC coverage criteria are met: pediatric age, appropriate clinical indication (complex NDD/ASD), prior nondiagnostic CMA, specialist ordering provider (neurologist), and pre-test genetic counseling — therefore WES is covered.",1982,1655,3637
Case2496,baseline,without_policy,iter1,WES,The clinical note explicitly states whole exome sequencing (WES) is being requested prenatally.,Not Specified,Payer WES policies do not generally impose an age cutoff for prenatal/fetal testing; the patient is a fetus at 32 weeks but no age-based exclusion is specified in applicable WES coverage rules.,Not Specified,UnitedHealthcare policies typically require an appropriate ordering clinician and documentation but do not universally restrict ordering to one specific specialty in all circumstances; the record lists a neonatologist request but the policy does not explicitly prohibit that ordering provider.,Yes,"Medical indications in UHC WES criteria include fetal anomalies or strong suspicion of a genetic disorder (family history of early unexplained death and parental consanguinity increase AR risk) and the note documents fetal imaging concern and consanguinity, meeting clinical indication criteria.",No,"UHC prenatal WES criteria generally require prior recommended cytogenetic testing (eg, chromosomal microarray or karyotype) to be nondiagnostic before WES; only nondiagnostic FISH is documented, not CMA/karyotype, so required prior testing has not been completed.",Yes,"The patient has parental consanguinity and a family history of sudden unexplained death in a sibling <35, both relevant family history items that align with coverage considerations for WES.",No,"UHC typically requires documentation of pre‑test genetic counseling for clinical genomic testing; the record states no genetic counseling has been completed, so counseling requirement is unmet.",81415,The requested test is whole exome sequencing; CPT 81415 corresponds to exome sequence analysis (interpretation/reporting) and is the appropriate billing code among the provided options.,No,"Although medical indication and family history support WES, coverage prerequisites (documented prior recommended cytogenetic testing such as CMA/karyotype and documented pre‑test genetic counseling) are not met in the provided information, so under UHC criteria the test would not be covered as presented.",1995,1473,3468
Case6867,baseline,without_policy,iter1,BRCA1/2,The clinical note explicitly states she presents for BRCA1 and BRCA2 testing.,Not Specified,BCBS_FEP BRCA coverage is driven by personal/family cancer history rather than a strict patient age cutoff; the record gives current age (50) but the policy does not impose a single age exclusion for testing in this clinical context.,Not Specified,"BCBS_FEP policies generally require an appropriate ordering clinician and documentation of counseling but do not mandate a single specific specialty (physician, NP, or genetic counselor) to place the order; the record shows referral by an NP and documented genetic counseling.",Yes,"Under BCBS_FEP BRCA criteria, testing is covered for individuals with a personal history of breast cancer plus first‑degree relatives with BRCA‑related cancers (here: a brother with metastatic prostate cancer with intraductal features and a mother with breast cancer at age 50), which meets medical indication.",Yes,"BCBS_FEP does not require prior genetic testing for an affected individual with qualifying personal/family history; no prior genetic test was required and none are documented, so prior‑test requirements are satisfied.",Yes,"The patient has relevant first‑degree family history: a brother with metastatic prostate cancer (intraductal features) and a mother with breast cancer at age 50, which is relevant under BCBS_FEP BRCA criteria.",Yes,BCBS_FEP requires documentation of pre‑test genetic counseling for hereditary cancer testing; the record documents multiple pre‑test counseling visits with a genetic counselor.,81228,"BRCA1/2 single‑gene diagnostic sequencing is reported with gene‑specific molecular CPT(s); of the provided options, 81228 corresponds to single‑gene sequencing type coding applicable to BRCA testing.",Yes,"Based on BCBS_FEP coverage rules: qualifying personal history of breast cancer, relevant first‑degree family history (metastatic prostate in brother and mother with early breast cancer), and documented pre‑test genetic counseling, the requested BRCA1/2 test meets medical necessity and is covered.",1986,2906,4892
Case1130,baseline,without_policy,iter1,WES,The patient record explicitly states the patient is 'undergoing whole exome sequencing (WES) to assess for an underlying genetic etiology.',Not Specified,UHC WES coverage is driven by clinical indications rather than strict age cutoffs in policy language; no age-based exclusion or required age threshold is documented for WES in the applicable UHC criteria for this clinical scenario.,Not Specified,UHC WES policy defines clinical indications and documentation requirements but does not mandate a specific ordering provider specialty in the applicable coverage rules (no explicit restriction to genetics specialists is specified).,No,"Under UHC WES criteria, coverage is generally limited to patients with unexplained developmental delay/intellectual disability, multiple congenital anomalies, or a suspected genetic disorder with early onset/multi-system involvement or refractory/complex neurologic presentations after targeted testing. This 68‑year‑old has persistent seizures only, without documented early-onset, multisystem findings, or other qualifying features; thus she does not meet the specific medical indications.",No,"UHC typically requires prior appropriate targeted testing (e.g., epilepsy gene panel or other targeted molecular testing and/or chromosomal microarray depending on presentation) before WES. The record only notes nondiagnostic FISH; required prior targeted genetic testing or CMA is not documented.",No,"UHC allowance of WES may consider family history of a similar phenotype or consanguinity; the only family history reported is a sister with ovarian/fallopian/peritoneal carcinoma (reviewed in counseling), which is unrelated to the patient's seizure phenotype and does not satisfy family-history criteria relevant to WES for neurologic disease.",Yes,"UHC requires documentation of pretest genetic counseling for WES; the record indicates the patient has seen a genetic counselor multiple times with plans for post-test follow-up, meeting counseling requirements.",81415,The requested test is whole exome sequencing (proband-focused); the appropriate CPT for WES (proband only) is 81415.,No,"Applying UHC WES coverage rules: although counseling is documented, the patient does not meet the policy's specified medical indication (no qualifying developmental/multi-system or early-onset/refractory complex neurologic presentation) and required prior targeted testing/CMA is not documented. Therefore WES is not covered in this case per payer criteria.",1989,1482,3471
Case5303,baseline,without_policy,iter1,BRCA1/2,The clinical note states the patient was referred for BRCA1 and BRCA2 testing explicitly.,Not Specified,UHC BRCA coverage is driven by personal/family cancer history and age-at-diagnosis of affected relatives rather than a hard age cutoff for the proband; the patient’s age (37) is not a standalone age exclusion or explicit age-based eligibility criterion in the policy.,Not Specified,"UHC BRCA policies generally do not mandate a specific ordering provider specialty (any qualified clinician may order), and no specialty requirement is documented in the patient information.",No,"Per UHC BRCA medical criteria, coverage requires a personal history of BRCA-associated cancer or a family history meeting defined patterns (e.g., relatives with breast/ovarian/pancreatic/early-onset prostate or male breast cancer). The patient has no personal history of such cancers and the only family history reported is a brother who died suddenly under age 35 (not a BRCA-associated cancer), so the patient does not meet covered clinical indications.",Not Specified,UHC guidance often recommends testing an affected relative first when possible but does not universally require a prior specific genetic test in all situations; the chart documents no prior genetic testing but the policy does not define a single required prior test for all BRCA requests.,No,Coverage-relevant family history for BRCA testing requires relatives with BRCA-associated cancers; the reported family history (brother with sudden unexpected death <35) is not a BRCA-associated cancer and thus does not satisfy family-history criteria in UHC policy.,No,"UHC typically expects documentation of pre-test genetic counseling for BRCA testing; the record states no pre-test genetic counseling was conducted, so counseling requirements are not met.",81277,"From the provided CPT choices, 81277 is the option most consistent with BRCA1/BRCA2 molecular testing among the listed codes (other codes correspond to WES/WGS/CMA or different genes).",No,"Applying UHC BRCA coverage criteria: the patient lacks a personal history of BRCA-associated cancer, lacks a family history that meets UHC’s defined patterns for BRCA testing, and pre-test genetic counseling was not documented. Therefore the requested BRCA1/2 test does not meet coverage criteria.",1960,2436,4396
Case7447,baseline,without_policy,iter1,WGS,The clinical note explicitly states the cardiologist has ordered whole genome sequencing (WGS) for the fetus.,Not Specified,BCBS_FEP prenatal/diagnostic sequencing policies do not impose an age/gestational‑age exclusion for fetal WES/WGS; gestational age (33 weeks) does not conflict with any standard age limits.,Not Specified,Typical BCBS_FEP guidance does not mandate a specific ordering specialty for WES/WGS beyond an appropriate clinician; the ordering cardiologist is an appropriate prenatal specialist and no payer‑specific ordering provider restriction is documented in the record.,Yes,BCBS_FEP considers prenatal genomic sequencing medically indicated for fetuses with major structural anomalies when a genetic etiology is suspected and results may affect management. An isolated severe congenital heart defect on fetal imaging meets the 'major structural anomaly' clinical indication.,No,"BCBS_FEP coverage for prenatal WES/WGS typically requires prior standard cytogenetic testing (eg, karyotype and/or chromosomal microarray). The record notes prior fragile X testing (nondiagnostic) but does not document prior CMA/karyotype; thus required prior testing appears incomplete.",Not Specified,Family history criteria are not generally required or specified for prenatal WGS eligibility under BCBS_FEP; the maternal aunt with triple‑negative breast cancer is noted but is not a specified requirement for fetal WGS coverage in this context.,No,"BCBS_FEP and usual genomic testing policies require documented pre‑test genetic counseling for complex genomic tests. There is no documentation of pre‑test genetic counseling in the record, so counseling requirements are not met.",81425,CPT 81425 corresponds to whole genome sequencing (WGS) and best matches the ordered test.,No,"Although the fetal indication (severe structural heart defect) supports medical necessity, BCBS_FEP requires completion of prior cytogenetic testing (eg, CMA/karyotype) and documented pre‑test genetic counseling for prenatal WGS. Required prior tests and counseling are not documented, so coverage is not supported at this time.",1972,2008,3980
Case16126,baseline,without_policy,iter1,BRCA1/2,The clinical note states BRCA1 and BRCA2 testing has been ordered.,Not Specified,"BCBS_FEP BRCA coverage policies do not impose strict age cutoffs; eligibility is driven by personal/family cancer history rather than patient age, and no age-based exclusion is specified.",Not Specified,BCBS_FEP BRCA policies typically require appropriate documentation and counseling but do not mandate a specific ordering specialty; the record shows a gynecologist ordered testing but the payer policy does not explicitly restrict ordering provider type.,No,"BCBS_FEP covers BRCA testing for individuals meeting clinical criteria (personal history of relevant cancer or qualifying family history/NCCN criteria). This 6-week-old infant with multiple congenital anomalies has no personal history of breast/ovarian cancer and no documented qualifying family cancer history, so medical indication for BRCA1/2 testing is not met.",Not Specified,"BCBS_FEP BRCA policies do not require specific prior diagnostic genetic tests (e.g., FISH) prior to BRCA testing; the prior nondiagnostic FISH is not listed as a required prior test.",No,"BCBS_FEP BRCA eligibility is based on family cancer history (affected relatives, ages at diagnosis, etc.). The record reports parental consanguinity but provides no family history of breast/ovarian cancer meeting coverage criteria, so required family-history criteria are not met.",Yes,"BCBS_FEP generally requires or expects genetic counseling for BRCA testing. The record documents pre-test counseling completed and planned post-test follow-up, satisfying counseling expectations.",81277,"Of the provided CPT options, 81277 is the gene-specific code most consistent with BRCA1/BRCA2 molecular testing (the other codes correspond to WES/WGS or non-BRCA tests).",No,Under BCBS_FEP BRCA coverage rules testing is covered only when clinical/NCCN family or personal cancer history criteria are met. This 6-week-old infant lacks a qualifying personal or family cancer history despite counseling; therefore BRCA1/2 testing is not covered.,1967,1948,3915
Case4512,baseline,without_policy,iter1,WGS,The patient information explicitly states whole genome sequencing (WGS) is being pursued.,Not Specified,BCBS_FEP WGS/WES policies are generally indication-based and do not impose a strict age cut-off for testing in patients with suspected genetic disorders; no age restriction is specified for this adult (21 y/o) in the provided payer rules.,Not Specified,BCBS_FEP criteria typically require appropriate ordering by a qualified clinician but do not mandate a specific specialty in the general WGS policy provided; patient record shows referral from PCP but payer-specific specialty requirement is not specified.,Yes,Patient has a major congenital cardiac anomaly since birth and a sibling with a potentially heritable event—this constellation is consistent with a suspected genetic etiology and meets BCBS_FEP clinical indications for genome sequencing (suspected genetic disorder / congenital anomaly).,No,"BCBS_FEP policies for WGS commonly require prior appropriate testing (e.g., chromosomal microarray and/or targeted testing) before WGS/WES except in certain circumstances; the patient has had no prior genetic testing, so required prior tests have not been completed.",Yes,"There is a family history (sibling with brief resolved unexplained event suggestive of a heritable predisposition), which is relevant to eligibility per BCBS_FEP criteria that consider family history of a similar disorder.",Yes,"BCBS_FEP requires documented pre-test genetic counseling for WGS/WES; the record states pre-test counseling was completed with a genetic counselor and a post-test visit is planned, satisfying counseling requirements.",81425,The CPT code that corresponds to whole genome sequencing is 81425 (whole genome sequence analysis).,No,"Although the patient meets clinical indication, has relevant family history, and has completed pre-test counseling, BCBS_FEP typically requires prior testing (e.g., chromosomal microarray or targeted testing) before WGS; because no prior genetic testing has been performed, WGS would not be covered at this time under those payer criteria.",2006,1801,3807
Case1778,baseline,without_policy,iter1,WES,The clinical note explicitly states whole exome sequencing (WES) has been requested for diagnostic clarification of an ocular coloboma.,Not Specified,"Typical payer WES policies do not impose strict age cutoffs; the patient is 14 but no payer-specific age restriction is provided in the information, so age-based eligibility is not specified here.",Not Specified,"Most policies allow ordering by an appropriate licensed provider but specific specialty requirements (e.g., genetics specialist) are not provided in the case details, so ordering-provider requirements are not specified.",No,"Most payer WES criteria require multiple congenital anomalies, moderate–severe developmental delay/intellectual disability, or a strong suspicion of a Mendelian disorder; this patient has an isolated ocular coloboma without additional anomalies, developmental delay, or documented syndromic features, so he does not meet defined medical-indication criteria.",No,"Common coverage rules require prior appropriate cytogenomic testing (usually chromosomal microarray) or targeted testing before WES. Only FISH was done and was nondiagnostic; CMA was not documented, so required prior testing is not complete.",No,Family history or consanguinity relevant to WES eligibility is not reported in the provided information; therefore the patient does not have a documented family-history criterion supporting WES.,No,"Payer policies commonly require documented pre-test genetic counseling for WES; no genetic counseling information is provided, so counseling requirements are not met.",81415,"CPT 81415 corresponds to whole exome sequencing (clinical exome sequencing with interpretation), which matches the requested WES.",No,"Based on payer-style criteria applied here: the patient has an isolated ocular coloboma (not meeting typical WES medical-indication thresholds), required prior testing (CMA) is not documented, and genetic counseling is not documented; therefore the request does not meet coverage criteria.",1935,1966,3901
Case14155,baseline,without_policy,iter1,WGS,The clinical note explicitly states whole genome sequencing (WGS) has been requested to assess genetic contributors to the child's ASD.,Yes,"Cigna's WES/WGS coverage for unexplained neurodevelopmental disorders applies to pediatric patients; the patient is a 7-year-old child, which meets age-based pediatric eligibility.",Not Specified,The provided information does not document any Cigna-specific ordering-provider specialty requirement; Cigna policies commonly do not strictly limit ordering to a single specialty in the text available here.,Yes,"Cigna's WES/WGS medically necessary criteria include unexplained autism spectrum disorder/neurodevelopmental disorder — the patient has ASD, meeting the clinical indication.",No,"Cigna typically requires prior chromosomal microarray (CMA) as a first‑tier test for unexplained developmental delay/ASD unless contraindicated; the record states no prior genetic testing was done, so required prior testing was not completed.",No,"Although a maternal uncle has a severe immunologic disorder, this family history is not described as a similar neurodevelopmental phenotype and therefore does not meet family‑history criteria relevant to Cigna's WGS indications for ASD.",No,"Cigna's policy expects documentation of pre‑test genetic counseling or informed consent for WES/WGS; the family declined pre‑test genetic counseling, so counseling requirements are not met.",81425,The requested test is whole genome sequencing; CPT 81425 corresponds to WGS (sequencing of the whole genome).,No,"Although age and clinical indication (ASD) are met, required prior testing (CMA) has not been completed and pre‑test genetic counseling was declined. Per Cigna WES/WGS coverage requirements, these unmet prerequisites support a denial of coverage.",1989,1622,3611
Case13406,baseline,without_policy,iter1,WGS,"The note states: ""Whole genome sequencing (WGS) has been ordered by a medical geneticist.""",Yes,"UHC coverage for WES/WGS is aimed at pediatric patients with unexplained global developmental delay/ID or congenital anomalies; the patient is a 6-week-old infant with concern for global developmental delay, meeting pediatric age-based criteria.",Yes,"UHC generally requires ordering by a qualified clinician (e.g., medical geneticist or other appropriate specialist) for WES/WGS; the test was ordered by a medical geneticist, meeting that requirement.",Yes,"UHC defines medical necessity for WES/WGS for individuals with unexplained developmental delay/ intellectual disability or multiple congenital anomalies after initial evaluation; this infant has concern for global developmental delay and nondiagnostic prior workup, so a defined clinical indication is met.",Yes,"UHC policies require prior appropriate testing (chromosomal microarray) before WES/WGS for unexplained developmental delay; CMA was performed and nondiagnostic, satisfying the prior-test requirement.",Not Specified,"UHC WGS criteria do not specifically require family history/consanguinity in this scenario; while a sibling had a brief resolved unexplained event, the documentation does not establish a family history criterion required for coverage.",Yes,"UHC requires genetic counseling for WES/WGS; pre-test counseling was completed and post-test follow-up with a genetic counselor is planned, meeting counseling requirements.",81425,"CPT 81425 corresponds to clinical germline whole genome sequencing (WGS), which matches the ordered test.",Yes,"Applying UHC coverage criteria: the patient is pediatric (6 weeks) with unexplained global developmental delay, prior CMA was nondiagnostic, the ordering provider is a medical geneticist, and pre-test counseling was completed — collectively meeting UHC medical necessity and coverage requirements for WGS.",2004,1705,3709
Case3581,baseline,without_policy,iter1,BRCA1/2,The clinical note states BRCA1 and BRCA2 testing has been ordered.,Not Specified,Cigna BRCA coverage criteria are based on personal/family cancer history and not on specific age cutoffs; the patient's age (69) does not invoke a separate exclusion or special age-based rule in routine BRCA policies.,Not Specified,Cigna policies do not generally restrict BRCA test ordering to a specific specialty in the documentation provided; no provider-type restriction is specified in the patient information.,No,"Cigna BRCA coverage requires personal and/or family history of BRCA-associated cancers or known familial BRCA mutation. The patient’s indication (hearing/visual impairment since age 18) and the sibling’s BRUE-like event are not BRCA-associated clinical indications, so the medical-necessity criteria are not met.",Not Specified,Cigna BRCA criteria do not require prior FISH or other cytogenetic testing before BRCA sequencing; the prior nondiagnostic FISH does not satisfy or substitute for any stated prerequisite testing requirement.,No,"Cigna’s family-history criteria for BRCA testing require a personal/family history of breast, ovarian, pancreatic, or related BRCA-associated cancers or a known familial BRCA mutation. The provided family history (a sibling with a brief resolved unexplained event) is not relevant to BRCA eligibility.",No,"Cigna BRCA policies typically require documented pre-test genetic counseling or counseling by a qualified provider; the record states no pre-test genetic counseling was conducted, so counseling requirements are not met.",Not Specified,"None of the listed CPT options clearly correspond to full BRCA1/2 testing (commonly billed as specific BRCA CPT codes not listed here), so an exact match from the provided choices cannot be determined.",No,Under Cigna BRCA coverage criteria the request is not medically indicated (no personal/family history of BRCA-associated cancer or known familial mutation) and required pre-test genetic counseling is absent; therefore the test is not covered.,1989,1422,3411
Case10529,baseline,without_policy,iter1,WES,The patient information explicitly states whole exome sequencing (WES) is being pursued.,Not Specified,UHC WES coverage criteria are typically indication-based rather than age-limited; no explicit age restriction is specified and the child is 6 years old.,Yes,"Ordering was by neurology (specialist referral). UHC permits orders from treating physicians/specialists (e.g., neurologists) when documentation supports the indication.",Yes,"UHC coverage criteria list unexplained developmental delay/intellectual disability as an indication for WES; the child has nonsyndromic developmental delay and intellectual disability, meeting that clinical criterion.",No,"UHC typically requires prior first‑tier testing (chromosomal microarray) and often Fragile X when applicable. Fragile X was nondiagnostic but CMA is not documented as completed, so required prior testing is incomplete.",Yes,Family history of neurologic disease (maternal uncle with dystonia and ataxia) is present and is relevant per UHC criteria as supportive information for genetic evaluation.,Yes,"Pre-test genetic counseling has been completed with plans for post-test follow-up, which satisfies UHC counseling/documentation requirements for WES.",81415,"CPT 81415 corresponds to exome sequencing (proband or single exome), which matches the requested WES.",No,"Although the clinical indication, ordering provider, counseling, and Fragile X testing meet UHC criteria, the absence of a documented chromosomal microarray (required prior test) means UHC coverage criteria are not fully met; therefore the WES request would not be covered as submitted.",1987,1721,3708
Case18821,baseline,without_policy,iter1,WES,The obstetrician explicitly requests fetal whole exome sequencing (WES) at 22 weeks to evaluate a suspected genetic etiology for multiple congenital anomalies.,Not Specified,BCBS FEP WES policy does not impose specific age or gestational‑age cutoffs for WES eligibility; the request concerns a fetus at 22 weeks and age-based criteria are not specified.,No,"BCBS FEP WES coverage typically requires ordering/oversight by or documentation of consultation with a clinical genetics provider (geneticist or genetic counselor). The request is from an obstetrician with no documented genetics consultation, so ordering provider requirements are not met.",Yes,"BCBS FEP allows WES for suspected monogenic disorders or fetuses with multiple congenital anomalies affecting different organ systems; the fetus has multiple anomalies on prenatal imaging, meeting a defined medical indication.",No,"BCBS FEP WES usually requires prior standard chromosomal evaluation (e.g., chromosomal microarray and/or karyotype) before WES in the prenatal setting; no prior genetic testing (CMA/karyotype) has been completed.",Yes,Family history can be relevant to WES eligibility; the report of a maternal aunt with dysmorphic features is a positive family history that is potentially relevant to the fetal phenotype.,No,BCBS FEP policy requires documentation of pre‑test genetic counseling for WES; there is no documentation of pre‑test genetic counseling in the provided information.,81415,CPT 81415 corresponds to clinical whole exome sequencing (proband/exome sequencing) and best matches the requested fetal WES.,No,"Although the fetal phenotype (multiple anomalies) meets a medical indication for WES per BCBS FEP, coverage prerequisites (documentation of prior chromosomal testing such as CMA/karyotype, documented pre‑test genetic counseling, and genetics ordering/consultation) are not met; therefore the test is not covered as requested.",1991,1982,3973
Case5230,baseline,without_policy,iter1,WES,The clinical note explicitly states whole exome sequencing (WES) was ordered to evaluate a congenital anomaly after nondiagnostic CMA.,Not Specified,UHC genomic sequencing policy does not impose a strict single age cutoff for WES; no age-based exclusion applies in the provided clinical scenario (patient is 15).,Not Specified,Typical UHC criteria do not mandate a narrowly defined ordering provider specialty for WES (order by an appropriate clinician is sufficient); the record shows referral from neurology but no disqualifying provider issue is present.,Yes,"UHC covers WES for individuals with unexplained congenital anomalies or suspected single-gene disorders when prior targeted testing/CMA is nondiagnostic; the patient has a congenital anomaly and nondiagnostic CMA, meeting that indication.",Yes,UHC requires prior chromosome microarray or other appropriate targeted testing before WES where indicated; the patient had a nondiagnostic CMA as stated.,Yes,Family history of a sibling with an inborn error of metabolism is relevant and supportive per UHC criteria that consider family history of a genetic disorder as supporting evidence for sequencing.,No,"UHC policies require documentation of pre- and/or post-test genetic counseling for genomic sequencing; the patient declined genetic counseling, so counseling requirements are not met.",81415,"CPT 81415 corresponds to clinical exome sequencing (proband-only), which best matches the ordered WES for this patient.",No,"Although the patient meets clinical indications and prior CMA was nondiagnostic (supporting medical necessity under UHC), required genetic counseling was declined and not documented; failure to meet the counseling requirement means coverage criteria are not fully satisfied.",1953,1599,3552
Case6478,baseline,without_policy,iter1,BRCA1/2,The referral explicitly requests germline BRCA1 and BRCA2 testing.,Not Specified,UnitedHealthcare BRCA policies do not impose a specific age cutoff for germline BRCA1/2 testing in adults; the patient is 52 but age-based restrictions are not specified.,Not Specified,UHC generally allows licensed ordering providers (physician/advanced practitioner) to order BRCA testing; no specialty-only ordering requirement is specified in the provided clinical information.,Yes,"Patient has metastatic prostate cancer, which is an established medical indication for germline BRCA1/2 testing under UHC hereditary cancer testing criteria to inform therapy and familial risk.",Not Specified,"There are no UHC-required prior diagnostic tests (e.g., tumor testing) universally required before germline BRCA1/2 testing in this clinical scenario; the patient has had no prior genetic testing but none is mandated as a prerequisite.",Yes,Family history of a first‑degree relative with pancreatic cancer (a BRCA‑associated malignancy) is relevant to BRCA testing eligibility and supports testing under UHC criteria.,No,"UHC hereditary cancer testing guidance expects documentation of genetic counseling/informed consent for BRCA testing; pre-test genetic counseling was not completed per the chart, so counseling requirements are not met.",81277,"Of the provided CPT options, 81277 most closely corresponds to BRCA1/BRCA2 germline testing (selected as the best available match for BRCA1/2 testing).",No,"Although the patient meets clinical indications (metastatic prostate cancer and relevant family history), the lack of documented pre-test genetic counseling (a UHC-required element for hereditary BRCA testing) means coverage criteria are not fully met and the test would not be approved as submitted.",1976,2525,4501
Case13613,baseline,without_policy,iter1,WES,The record explicitly states whole exome sequencing (WES) was requested for the fetus at 22 weeks for evaluation of multiple structural anomalies.,Not Specified,UnitedHealthcare WES coverage criteria are applied and do not impose a strict chronological age cutoff for prenatal/fetal testing; the patient is a 22‑week fetus which falls within prenatal indications but payer age limits are not specified.,Yes,"UHC WES policies require ordering/consultation by or documentation of discussion with an appropriate specialist (e.g., geneticist/genetic counselor). The case documents a referral by neurology and a pre‑test discussion with a genetic specialist, satisfying provider requirements.",Yes,UHC covers WES for unexplained multiple congenital/structural anomalies detected on prenatal imaging; the fetus has multiple structural anomalies on ultrasound meeting that clinical indication.,No,"UHC prenatal WES typically requires prior standard diagnostic testing (e.g., chromosomal microarray/karyotype) to be non‑diagnostic before WES. Only fragile X testing is documented (nondiagnostic); no CMA/karyotype is documented, so required prior testing is not complete.",Yes,"Family history criteria are relevant for genetic evaluation; the record notes a maternal aunt with dysmorphic features, which is pertinent to the WES indication.",Yes,"UHC requires pre‑test genetic counseling for WES. The record documents a pre‑test discussion with a genetic specialist, meeting counseling requirements.",81415,"The requested test is whole exome sequencing (proband/fetal exome), which corresponds to CPT 81415 for exome sequencing (proband).",No,"Although clinical indication, specialist involvement, counseling, and family history support WES, UnitedHealthcare requires prior standard cytogenomic testing (e.g., chromosomal microarray/karyotype) be non‑diagnostic before WES; those prior tests are not documented, so coverage would be denied until required prior testing is completed/documented.",1978,1792,3770
Case5380,baseline,without_policy,iter1,WGS,The clinical note explicitly states 'whole genome sequencing (WGS) is requested.',Not Specified,"UHC WGS/WES coverage criteria are applied to clinical indications rather than a strict age cutoff; no payer-specific age exclusion for infants is indicated in the policy, so age-based criteria are not specified.",Yes,"UHC allows appropriate specialists (e.g., pediatric neurologists) to order advanced genomic testing; the referral is from neurology which meets typical ordering-provider requirements in UHC policy.",Yes,UHC medical necessity criteria support WGS/WES for infants with unexplained recurrent seizures/BRUE to identify an underlying genetic etiology; the patient has recurrent seizure‑like events fitting that indication.,Yes,"UHC generally requires prior chromosomal microarray for unexplained neurodevelopmental disorders before WES/WGS when applicable; the patient had a nondiagnostic CMA, satisfying that prior-test requirement.",Not Specified,"UHC WGS coverage is based on clinical phenotype (e.g., unexplained seizures); specific family-history or consanguinity criteria are not required for coverage in this context, so family history is not a specified criterion.",No,"UHC policy requires documentation of pre-test genetic counseling by a qualified provider for WGS/WES; the family declined pre-test genetic counseling, so counseling requirements are not met.",81425,The requested test is whole genome sequencing; CPT code 81425 corresponds to WGS (interpretation and report).,No,"Although indication, prior CMA, ordering provider, and age are appropriate per UHC criteria, the required pre-test genetic counseling was declined and not documented; per UHC coverage policy this missing counseling requirement results in noncoverage.",1981,1418,3399
Case15570,baseline,without_policy,iter1,BRCA1/2,Provider explicitly requested BRCA1 and BRCA2 testing per the patient information.,Not Specified,BCBS FEP BRCA coverage is based on personal/family cancer history rather than strict age cutoffs; no age-based exclusion or specific minimum age is documented in the payer criteria relevant to this case.,Not Specified,BCBS FEP policies typically do not restrict BRCA ordering to a specific specialty in policy language; the record lists a general pediatrician but payer ordering-provider restrictions are not specified in the provided policy context.,No,"BCBS FEP BRCA coverage requires a personal and/or family history meeting hereditary breast/ovarian cancer criteria. The patient has Hirschsprung disease with no personal cancer history and no documented family cancer history, so medical indication criteria are not met.",Not Specified,"Payer BRCA criteria do not require prior diagnostic genetic tests (e.g., karyotype) before BRCA1/2 sequencing; no specific prior-test prerequisites are identified in the applicable coverage criteria for BRCA in this scenario.",No,"BCBS FEP BRCA eligibility relies on family history of breast/ovarian (or related) cancers. The family history provided (mother with bipolar disorder) contains no relevant cancer history, so family-history criteria are not met.",No,"BCBS FEP generally expects documentation of pre-test genetic counseling for hereditary cancer testing; there is no documentation of pre-test genetic counseling for this patient, so counseling requirements are not satisfied.",Not Specified,"The typical BRCA-specific CPT codes (e.g., single-gene BRCA1/BRCA2 codes) are not among the provided options; therefore an exact match from the list cannot be specified.",No,"Under BCBS FEP criteria BRCA testing is covered when personal/family cancer history or other specified indications are met and counseling documented. This patient lacks qualifying personal/family cancer history and pre-test counseling, so the test does not meet coverage criteria.",1979,2242,4221
Case5834,baseline,without_policy,iter1,CMA,The clinical note explicitly states a referral for chromosomal microarray (CMA) testing to evaluate a genomic etiology for the patient's developmental disorder.,Not Specified,BCBS FEP CMA coverage is driven by clinical indication (unexplained intellectual disability/developmental delay) rather than a strict age cutoff; no payer age-based exclusion is specified that would bar testing for this 67‑year‑old.,Not Specified,"BCBS FEP medical policy does not mandate a specific ordering provider specialty for CMA (documentation of clinical indication and counseling is required), and no specialty requirement is provided in the patient data.",Yes,"BCBS FEP considers CMA medically indicated as a first‑line test for individuals with unexplained intellectual disability/developmental delay; the patient has lifelong severe intellectual disability diagnosed by age 18, meeting that clinical criterion.",Not Specified,BCBS FEP policy treats CMA as a first‑line test for unexplained intellectual disability and does not require prior cytogenetic testing/karyotype before CMA; the patient had no prior testing but no prior-test prerequisite is specified.,Not Specified,Family history/consanguinity criteria are not required for CMA coverage in the context of unexplained intellectual disability; the noted maternal ovarian cancer is not relevant to CMA eligibility under BCBS FEP rules.,Yes,"BCBS FEP expects documentation of pre‑test genetic counseling for complex genomic testing; the record documents multiple pre‑test counseling sessions with a genetic counselor and plans for post‑test follow‑up, satisfying this requirement.",81415,The requested test is chromosomal microarray; the most appropriate CPT choice among the options provided is 81415 (microarray/genomic copy number analysis code in the offered list).,Yes,"Under BCBS FEP criteria CMA is covered for unexplained intellectual disability/developmental delay, the patient meets the clinical indication, pre‑test genetic counseling is documented, and no disqualifying age or prior‑test requirements apply.",2002,2565,4567
Case1501,baseline,without_policy,iter1,WES,The case text explicitly states that Whole Exome Sequencing (WES) is being ordered.,Not Specified,"UHC WES coverage criteria do not impose a strict age cutoff for WES; pediatric patients are routinely eligible, and no age-based exclusion is stated for this indication.",Not Specified,"UHC policies typically require that testing be ordered with appropriate documentation and genetic counseling but do not strictly limit ordering to a single specialty in the policy text; the patient was referred by a developmental pediatrician and had pre-test counseling, which meets usual provider/counseling expectations.",Yes,"UHC covers WES for individuals with unexplained developmental delay/intellectual disability and/or multiple congenital anomalies when a monogenic etiology is suspected; this 2‑year‑old has multiple congenital anomalies and ongoing developmental concerns, satisfying those clinical indications.",No,"UHC WES policy requires prior appropriate testing (e.g., chromosomal microarray) to be nondiagnostic before WES for developmental delay/congenital anomalies. Only a nondiagnostic karyotype is documented; no CMA result is provided, so the required prior test has not been completed.",Yes,The patient has a relevant family history (mother with Long QT syndrome). Family history of a genetic disorder is present and can be relevant to genetic testing decisions per coverage considerations.,Yes,"UHC requires pre-test genetic counseling for targeted and comprehensive genomic testing; the record states pre-test genetic counseling was completed and post-test follow-up is planned, meeting counseling requirements.",81415,"CPT 81415 corresponds to exome sequencing (proband-only), which best matches the ordered WES in this scenario.",No,"Although clinical indications and counseling requirements are met, UHC policy requires prior appropriate testing (typically chromosomal microarray) to be nondiagnostic before WES for developmental delay/multiple congenital anomalies; CMA was not documented, so coverage criteria are not fully met.",1975,1589,3564
Case10427,baseline,without_policy,iter1,WGS,Clinical note explicitly states whole genome sequencing (WGS) is being requested.,Yes,UHC WGS/WES policy defines pediatric/early-onset neurodevelopmental presentations as eligible; the patient is an 8-week-old infant and thus meets the age-based (pediatric) eligibility.,Not Specified,UHC policy requires an ordering clinician and documentation but does not strictly limit ordering to a specific named specialty in routine language; the neurologist referral is appropriate but a specific specialty requirement is not explicitly specified in the provided policy context.,Yes,"UHC coverage criteria include unexplained hypotonia/early-onset neurodevelopmental disorder or progressive neurologic presentations as indications for WGS/WES; the infant has significant hypotonia and a family history of regression, meeting an indicated clinical criterion.",No,"UHC generally requires prior appropriate first‑line testing (eg, chromosomal microarray and other targeted testing such as Fragile X when indicated) before WGS/WES; only FISH was performed and CMA (and other required prior tests) are not documented as completed.",Yes,"Family history is relevant: an older sibling had unexplained developmental regression, which is pertinent to genetic testing eligibility per payer criteria.",Yes,"UHC requires pre‑test genetic counseling and informed consent for WGS/WES; the record documents pre‑test counseling with a genetic counselor and planned post‑test follow‑up, meeting counseling requirements.",81425,CPT 81425 corresponds to whole genome sequencing (WGS) analysis and interpretation.,No,"Although age, clinical indication, family history, and counseling meet UHC criteria, required prior testing (eg, chromosomal microarray) is not documented; per UHC policy this unmet prior‑testing requirement means WGS would not be covered at this time.",1993,1886,3879
Case8485,baseline,without_policy,iter1,WES,The patient information explicitly states whole exome sequencing (WES) has been ordered.,Not Specified,"Cigna WES coverage criteria do not impose a strict age cutoff; pediatric patients with unexplained developmental delay/intellectual disability are eligible, so no specific age restriction is specified.",Not Specified,Cigna policies typically require an appropriate ordering provider and documentation but do not universally restrict ordering to a genetics specialist; the record lists a general pediatrician and no payer-specific prohibition is provided.,Yes,"Cigna considers WES medically indicated for unexplained developmental/motor delay and evolving neurologic findings in a child; this 8-year-old has persistent motor delay, hypotonia from infancy, and evolving tone abnormalities, meeting clinical indication criteria.",No,"Cigna generally requires prior first‑line testing (e.g., chromosomal microarray and, when applicable, Fragile X testing) before WES; Fragile X was nondiagnostic but no CMA is reported, so required prior testing is incomplete.",Yes,"Family history can be supportive in Cigna criteria; the family reports a sibling with autism spectrum disorder, which is a relevant first-degree family history supporting genetic evaluation.",No,"Cigna typically requires documentation of pre-test genetic counseling for WES; the record states pre-test genetic counseling was not performed, so counseling requirements are not met.",81415,CPT 81415 corresponds to whole exome sequencing (proband/exome sequencing) and best matches the ordered test (WES).,No,"Although the clinical indication is met, Cigna coverage conditions (required prior testing—CMA—and documentation of pre‑test genetic counseling) are not satisfied; therefore coverage would not be approved as submitted.",1971,1675,3646
Case11795,baseline,without_policy,iter1,WES,The patient information explicitly states that whole exome sequencing (WES) is being ordered after a nondiagnostic CMA.,Yes,BCBS_FEP WES coverage criteria include pediatric/neonatal patients with suspected genetic disorders or unexplained congenital/neurologic/cardiac findings; the patient is a 3‑week‑old infant and therefore meets age‑related eligibility for pediatric WES.,Not Specified,BCBS_FEP policy requires an appropriate ordering clinician and documentation of medical necessity and counseling but does not strictly limit ordering to a specific specialty in the policy language provided; the referral is from a cardiologist which is an appropriate treating physician.,Yes,"Policy indications for WES include suspected genetic disorders in infants with significant unexplained findings (serious cardiac conduction/arrhythmia/cardiomyopathy or complex phenotype) and prior nondiagnostic chromosomal testing; the infant has a markedly abnormal ECG concerning for channelopathy/arrhythmia/cardiomyopathy and CMA was nondiagnostic, satisfying medical-necessity criteria.",Yes,"BCBS_FEP WES criteria generally require prior chromosomal microarray for unexplained developmental/congenital disorders; CMA was previously performed and nondiagnostic, meeting the required prior testing step.",Yes,The patient has a sibling with moderate–severe intellectual disability diagnosed in childhood; BCBS_FEP considers relevant family history as supporting indication for broader genetic testing such as WES.,Yes,"BCBS_FEP requires documentation of pre‑test genetic counseling for WES; the record states pre‑test counseling was completed with plans for post‑test follow‑up, meeting counseling requirements.",81415,"CPT 81415 corresponds to clinical whole exome sequencing (WES) interpretation and report, which best matches the requested test; no trio CPT was specified.",Yes,"Under BCBS_FEP WES coverage criteria the infant meets age and clinical indication requirements (serious neonatal cardiac findings, prior nondiagnostic CMA), required prior testing is complete, pre‑test counseling documented, and the appropriate CPT (81415) is identified — overall supporting coverage of WES.",2021,2267,4288
Case2007,baseline,without_policy,iter1,BRCA1/2,Referral explicitly requests BRCA1 and BRCA2 testing.,Yes,"BCBS_FEP hereditary breast/ovarian cancer criteria specify early-onset breast cancer (e.g., diagnosis ≤50) as an indication for BRCA testing; the patient is 18, which meets the age-based criterion.",Not Specified,BCBS_FEP policies require documentation of counseling but typically do not mandate a specific ordering physician specialty; the case lists a family medicine physician referral but policy does not specify an ordering-provider specialty requirement.,Yes,Patient has a personal history of metastatic breast cancer at a young age plus a first-degree relative (mother) with breast cancer diagnosed ≤50 — both meet BCBS_FEP medical indications for BRCA1/2 germline testing.,Not Specified,BCBS_FEP BRCA coverage does not require prior chromosomal microarray or other specific prior genetic tests; the prior CMA being nondiagnostic is noted but not required for BRCA testing.,Yes,"Family history is relevant: mother had breast cancer at age ≤50, which is a qualifying family-history criterion in BCBS_FEP BRCA coverage rules.",Yes,"BCBS_FEP requires documentation of pre-test genetic counseling for BRCA testing; the patient completed pre-test counseling and will return for post-test counseling, meeting counseling requirements.",81228,CPT 81228 corresponds to BRCA1/BRCA2 germline testing (comprehensive analysis) and best matches the requested BRCA1/2 test.,Yes,"Per BCBS_FEP coverage criteria the patient meets medical indications (personal early-onset breast cancer and qualifying family history), has required pre-test counseling documented, and no disqualifying prior-test requirements apply; therefore BRCA1/2 testing is covered.",1980,1945,3925
Case7297,baseline,without_policy,iter1,WES,Patient information explicitly states whole exome sequencing (WES) is being pursued.,Yes,"UHC WES criteria apply to pediatric patients with unexplained multiple congenital anomalies/developmental concerns; the patient is 3 years old, meeting age-related pediatric eligibility.",Yes,"UHC requires genetic counseling/appropriate genetics involvement for WES but does not mandate a specific ordering specialty; pre-test counseling was completed with a genetic specialist, satisfying provider/counseling requirements.",Yes,"UHC medical-necessity criteria for WES include unexplained multiple congenital anomalies affecting multiple organ systems; the child has multiple congenital anomalies involving different organ systems, meeting an indication.",No,"UHC typically requires prior appropriate cytogenetic testing such as chromosomal microarray (CMA) before WES for multiple congenital anomalies. Only a nondiagnostic karyotype is documented; no CMA result is provided, so required prior testing is incomplete.",No,"Family-history criteria for WES focus on relatives with similar phenotypes or consanguinity. The only family history noted is a maternal aunt with ovarian cancer, which is not a relevant affected relative for the child’s congenital anomaly phenotype.",Yes,"UHC requires documentation of pre-test genetic counseling for WES. The record states pre-test counseling was completed with a genetic specialist and post-test follow-up is planned, meeting counseling requirements.",81415,CPT 81415 corresponds to clinical exome sequencing (WES) for a proband; this best matches the requested test.,No,"Although age, clinical indication, and counseling requirements are met, UHC policy requires prior appropriate cytogenetic testing (typically CMA) before WES for multiple congenital anomalies; CMA is not documented, so coverage would be denied until required prior testing is completed.",1997,2072,4069
Case2666,baseline,without_policy,iter1,BRCA1/2,The clinical note states she is undergoing BRCA1/2 testing at the request of her obstetrician.,Not Specified,BCBS FEP BRCA coverage is based on personal/family cancer history rather than a strict age cutoff; no age-specific exclusion/threshold is specified and the patient is an adult (21).,Not Specified,"FEP policy does not limit ordering to a narrow specialty; requirements focus on counseling/documentation rather than that the order come only from a geneticist, and the record shows an obstetrician ordered the test.",Yes,"FEP coverage criteria include individuals with a first-degree relative with BRCA-associated cancers such as metastatic prostate cancer; the patient’s father has metastatic prostate cancer (first-degree), meeting medical indication for BRCA1/2 testing.",Not Specified,There are no FEP requirements for completion of specific prior tests before BRCA1/2 sequencing; the prior nondiagnostic FISH is unrelated to BRCA testing.,Yes,Family-history criteria are specified for BRCA testing and she has a relevant first-degree family history (father with metastatic prostate cancer).,Yes,"FEP BRCA policy requires documentation of pre-test genetic counseling; the record documents pre-test counseling with a genetic specialist and planned post-test follow-up, satisfying counseling requirements.",Not Specified,"The usual single-gene BRCA1/2 CPT codes (e.g., 81211/81213) are not among the provided options; none of the listed CPT codes clearly correspond to standard BRCA1/2 single-gene testing.",Yes,She meets FEP medical-necessity family-history criteria (first-degree relative with metastatic prostate cancer) and has documented pre-test genetic counseling; therefore BRCA1/2 testing is covered.,1980,2139,4119
Case13983,baseline,without_policy,iter1,WGS,The clinical note explicitly states whole genome sequencing (WGS) is being pursued at the ordering provider's request.,Not Specified,BCBS_FEP genomic sequencing policies generally apply to pediatric and adult patients with suspected genetic disorders but do not impose a strict single age cutoff; the patient is a 7‑week‑old infant and no payer age exclusion is specified.,Not Specified,"BCBS_FEP policies require appropriate documentation and counseling but typically do not restrict ordering to a specific specialty in all situations; the record documents that testing was requested by the clinician and pre‑test counseling was done, and no explicit payer ordering‑provider restriction is provided.",Yes,The infant has a high‑risk BRUE with a significantly abnormal ECG suggesting possible channelopathy/arrhythmia/cardiomyopathy plus relevant family history—this meets BCBS_FEP clinical indications for genomic sequencing for a suspected genetic disorder that could explain and affect management.,No,"BCBS_FEP sequencing criteria commonly expect prior targeted testing (for example chromosomal microarray or relevant targeted panels) to be nondiagnostic unless WGS/WES is being done as first‑line in an acutely ill infant; only FISH was documented as nondiagnostic and no CMA or targeted gene panel is documented, so required prior testing is not fully documented.",Yes,A maternal uncle with unexplained developmental regression is documented; BCBS_FEP considers relevant family history when assessing need for genomic sequencing.,Yes,"Pre‑test counseling was completed with a genetic counselor and post‑test follow‑up is planned, satisfying BCBS_FEP counseling requirements for genomic testing.",81425,The service requested is whole genome sequencing; CPT code 81425 corresponds to whole genome sequence analysis/reporting and is the appropriate code for WGS.,Yes,"Under BCBS_FEP coverage principles, WGS is considered medically necessary for infants with a suspected genetic disorder that is likely to affect acute management (significant abnormal ECG raising concern for channelopathy/arrhythmia/cardiomyopathy), family history, and when prior testing is nondiagnostic. Pre‑test genetic counseling is documented. Although additional prior tests (e.g., CMA or targeted panels) are not all documented, the clinical urgency and potential management impact support coverage.",2045,2425,4470
Case15458,baseline,without_policy,iter1,BRCA1/2,Patient is explicitly being evaluated for BRCA1 and BRCA2 testing per the clinical information.,Yes,BCBS_FEP BRCA coverage uses clinical-age thresholds (early-onset breast cancer and strong family history) — a 19‑year‑old with personal history of breast cancer meets age-related criteria for testing.,Not Specified,"BCBS_FEP policy focuses on clinical indications and counseling; it does not explicitly restrict ordering to a physician only. The record shows a nurse practitioner ordered testing, which is typically allowed within scope of practice, but the payer policy does not specifically state single-provider-type requirements.",Yes,"Clinical indications in BCBS_FEP BRCA policy include personal history of breast cancer at a very young age and/or family history of ovarian/prostate cancer; the patient has a personal history of breast cancer at 19 plus a maternal aunt with ovarian cancer, satisfying medical necessity criteria.",Not Specified,"BCBS_FEP BRCA policy does not mandate completion of specific prior tests (the reported nondiagnostic FISH is not a standard required precursor), so no prior-test prerequisite is specified.",Yes,"Family-history criteria are part of BRCA coverage rules; the patient has a maternal aunt with ovarian cancer and another close relative with prostate cancer, which supports testing eligibility under BCBS_FEP criteria.",Yes,"BCBS_FEP requires (or strongly recommends) pre-test genetic counseling for BRCA testing; the patient completed pre-test counseling with planned post-test follow-up, meeting counseling requirements.",81228,The requested service is diagnostic BRCA1/BRCA2 gene testing; the CPT option most consistent with comprehensive BRCA1/2 sequence analysis among the provided choices is 81228.,Yes,"Under BCBS_FEP BRCA coverage criteria the patient meets medical necessity (very early-onset breast cancer plus supporting family history), counseling requirements are met, and no disqualifying prior-test or provider restrictions apply — test is covered.",1991,1983,3974
Case18868,baseline,without_policy,iter1,WGS,The clinical note explicitly states whole genome sequencing (WGS) has been ordered to assess for an underlying hereditary cancer predisposition.,No,Cigna WES/WGS clinical coverage is age‑restricted toward pediatric/onset genetic disorders (adult WGS for hereditary cancer is not an age‑indication). The patient is 41 and does not meet the age‑related pediatric/onset criteria in the payer's WES/WGS policy.,Yes,"Cigna policies that allow WES/WGS require ordering by or documented evaluation with a genetics specialist; the patient was evaluated by a medical geneticist who ordered the test, meeting provider requirements.",No,"Cigna's defined medical indications for WGS/WES are generally for unexplained developmental delay, congenital anomalies, or complex pediatric neurologic disorders—not adult hereditary cancer predisposition. The patient's indication (adult primary peritoneal carcinoma to evaluate hereditary cancer risk) does not meet the payer's specific WGS/WES indications.",No,"Cigna typically requires completion of indicated targeted testing (e.g., guideline‑directed single gene or multi‑gene cancer panel testing and/or chromosomal microarray where appropriate) prior to WES/WGS. The record shows only a nondiagnostic karyotype (not CMA) and no prior targeted germline cancer panel, so required prior testing has not been completed.",Yes,"The patient has a relevant family history: the mother has a persistent, severe hematologic disorder raising concern for a heritable syndrome affecting cancer and hematologic risk; this family history is relevant to consideration of hereditary testing.",No,"Cigna requires documented pre‑test genetic counseling for complex genomic tests like WES/WGS. The materials provided contain no documented pre‑test counseling, so counseling requirements are not met.",81425,The requested test is whole genome sequencing; CPT 81425 corresponds to comprehensive genome sequence analysis (WGS) in typical billing nomenclature.,No,"Under Cigna clinical coverage, WGS for an adult with suspected hereditary cancer predisposition is not a covered indication (WES/WGS reserved for specific pediatric/complex indications). Required prior targeted testing and documented pre‑test genetic counseling are lacking, so the request is not covered.",1989,1712,3701
Case10917,baseline,without_policy,iter1,WES,The case statement explicitly says whole exome sequencing (WES) has been ordered to evaluate for an underlying genetic cause.,Not Specified,UHC WES policy does not impose a strict age cutoff for WES; pediatric/infant testing is routinely considered. No age-based exclusion is specified for WES in the payer criteria.,Yes,"Payer criteria require appropriate ordering by a genetics provider or specialist for WES; the patient was evaluated by a medical geneticist and pre-test counseling was completed by a genetic specialist, meeting provider requirements.",Yes,"UHC considers WES medically indicated for infants with unexplained congenital/ multisystem anomalies or suspected monogenic disorders. The infant has persistent conjugated hyperbilirubinemia (not explained by TPN) and a sibling with multiple congenital anomalies, supporting a suspected genetic etiology.",No,UHC generally requires prior appropriate testing (commonly chromosomal microarray or other targeted testing) before WES for congenital anomalies. The record documents Fragile X testing (nondiagnostic) but does not document completion of CMA or other required prior tests.,Yes,"Family history is relevant under payer criteria. The patient has an older sibling with multiple congenital anomalies, which supports genetic testing per UHC indications.",Yes,UHC requires documentation of pre-test genetic counseling for WES; the record states pre-test counseling was completed with a genetic specialist.,81415,"CPT 81415 corresponds to clinical whole exome sequencing (proband only), which matches the ordered WES.",No,"Although clinical indications, provider type, and counseling meet UHC criteria, required prior testing (e.g., documented CMA or other specified prior diagnostic testing) is not documented. Per UHC policy, absence of required prior testing renders WES not covered in this case.",1984,1565,3549
Case12792,baseline,without_policy,iter1,BRCA1/2,The referral explicitly requested BRCA1/2 testing for this 12-year-old.,Not Specified,BCBS FEP coverage for BRCA testing is based on personal/family cancer history or known familial pathogenic variant rather than a strict age cutoff; no payer-specific age exclusion is noted in the provided context.,Not Specified,"The case states the test was ordered by a family medicine physician; BCBS FEP policies typically do not mandate a specific specialist for ordering BRCA testing beyond documentation of appropriate indication, and no explicit ordering-provider restriction is provided here.",No,BCBS FEP criteria require personal or family history of BRCA-related cancers or testing for a known familial pathogenic variant. The patient has congenital choanal atresia and a maternal growth abnormality—neither meets BRCA testing clinical indications.,Not Specified,There are no payer-specified prior testing requirements for BRCA1/2 sequencing in this scenario; the prior nondiagnostic FISH is unrelated to BRCA sequencing requirements.,No,"BRCA coverage criteria hinge on relevant family history of breast/ovarian (or related) cancers; the provided family history cites only a maternal growth abnormality, which is not a BRCA-relevant cancer history.",Yes,"BCBS FEP commonly requires documentation of genetic counseling for hereditary cancer testing. The record states pre-test genetic counseling was completed and post-test follow-up is planned, meeting counseling requirements.",81277,"Among the provided CPT choices, 81277 is the option in the single-gene molecular sequencing code range consistent with BRCA1/2 single-gene testing; other listed codes correspond to exome/genome or different assays.",No,"Although counseling is documented, BCBS FEP coverage requires appropriate personal or family history of BRCA-associated cancers or a known familial pathogenic variant. The patient lacks BRCA-relevant personal or family cancer history, so the test is not covered.",1963,2039,4002
Case8710,baseline,without_policy,iter1,WES,The chart explicitly states whole exome sequencing (WES) has been requested to investigate an underlying genetic etiology.,Not Specified,UHC WES policies do not impose an explicit age cutoff in typical coverage criteria for WES for neurodevelopmental disorders; the record lists a 12‑year‑old but no age restriction is specified by the payer policy.,Not Specified,The supplied information does not indicate any payer requirement that only certain provider specialties may order WES; the ordering provider is a developmental pediatrician but the policy's provider‑type requirement is not specified in the case data.,Yes,"From an insurer medical‑necessity perspective, UHC permits WES for unexplained autism spectrum disorder when there is at least one additional abnormality/multisystem involvement; the patient has ASD plus ≥1 additional organ‑system abnormality, meeting a defined clinical indication.",No,"UHC commonly requires prior chromosomal microarray (CMA) for developmental disorders prior to WES; the record documents a nondiagnostic karyotype but not a CMA, so required prior testing has not been completed.",Yes,"The patient has a relevant family history (paternal uncle with neurologic disease—dystonia/ataxia), which is supportive and potentially relevant to genetic testing eligibility per payer criteria.",No,UHC policies typically require documentation of pre‑test genetic counseling/informed consent for WES; no pre‑test genetic counseling is documented in the record.,81415,"CPT 81415 corresponds to clinical whole exome sequencing (proband) interpretation and report, which maps to the requested WES.",No,"Although the patient meets clinical indications for WES, coverage prerequisites per UHC (notably prior CMA testing and documentation of pre‑test genetic counseling) are not satisfied; therefore the test is not covered as submitted.",1991,2282,4273
Case16246,baseline,without_policy,iter1,BRCA1/2,The clinical note explicitly states the patient is being referred for BRCA1 and BRCA2 testing.,Yes,"UHC BRCA coverage includes women with personal history of breast cancer diagnosed <50 y/o; the patient is 35, meeting the age-based criterion.",Yes,UHC allows ordering by the treating physician or appropriate specialist; the test was ordered/referred by the patient's gynecologist (an accepted ordering provider).,Yes,UHC lists personal history of breast cancer diagnosed before age 50 as a covered clinical indication for BRCA1/2 testing; the patient meets this indication.,Not Specified,"UHC BRCA policies do not require prior genetic testing (e.g., karyotype) before BRCA1/2 sequencing; the provided prior karyotype is irrelevant and there is no required prior test documented.",Yes,"The patient reports an uncle with pancreatic cancer; UHC considers certain family histories (including pancreatic cancer) relevant to BRCA-related risk, and a family history is present.",No,UHC BRCA policies require that testing be accompanied by documented pre-test genetic counseling or counseling by an appropriate provider; the record states no pre-test genetic counseling was conducted.,81228,"The requested test is BRCA1/2 single-gene germline testing; among the provided CPT options, 81228 is the closest match for targeted hereditary cancer gene sequencing in this list.",No,"Although age, clinical indication, provider, and family-history criteria are met, required pre-test genetic counseling is not documented per UHC policy; lack of required counseling would preclude coverage approval at this time.",1974,2045,4019
Case14017,baseline,without_policy,iter1,WES,Patient record explicitly states whole exome sequencing (WES) has been ordered.,Not Specified,"BCBS FEP WES coverage criteria do not impose a strict age cutoff; pediatric patients (including infants) are routinely considered, so no age-based exclusion applies.",Not Specified,"The provided BCBS FEP coverage criteria do not mandate a specific ordering provider specialty in all cases; the chart shows a general pediatrician ordered testing and there is documented genetic counseling, which meets typical practice requirements.",Yes,Clinical indication meets common BCBS FEP WES indications: early infancy with recurrent seizure-like events/possible epileptic disorder and concern for an underlying genetic etiology.,No,BCBS FEP WES policy typically requires prior appropriate cytogenomic testing (chromosomal microarray) or targeted testing when indicated. Only a nondiagnostic karyotype is documented; no CMA or other required prior testing is reported.,Yes,"Patient has a relevant family history: a maternal uncle with a movement disorder (dystonia and ataxia), which supports a possible inherited neurologic etiology per coverage considerations.",Yes,"Pre-test genetic counseling was completed with plans for post-test follow-up, satisfying BCBS FEP counseling requirements for WES.",81415,"CPT 81415 corresponds to clinical whole exome sequencing, which is the test ordered.",No,"Although medical indication, counseling, and family history support WES, BCBS FEP coverage requirements commonly mandate prior appropriate cytogenomic testing (chromosomal microarray) or equivalent targeted testing before approving WES; only a nondiagnostic karyotype is documented and CMA was not completed, so coverage would be denied pending required prior testing.",2004,1609,3613
Case5674,baseline,without_policy,iter1,WES,The clinical note explicitly states the team plans whole exome sequencing (WES) to investigate a possible genetic epilepsy syndrome.,Yes,BCBS_FEP WES policy includes pediatric patients with suspected genetic neurologic disorders; the patient is 9 years old (pediatric) and thus meets age-based eligibility for WES.,Yes,"FEP typically requires clinician ordering with genetics involvement or consultation. Although the ordering clinician is a general practitioner, the record documents multiple visits with a genetic counselor and arranged genetics follow-up, satisfying the payer's provider/counseling involvement expectations.",Yes,"BCBS_FEP covers WES for unexplained, suspected genetic neurologic disorders such as persistent/early-onset seizures or suspected genetic epilepsy; the child has persistent seizures and concern for a genetic epilepsy syndrome, meeting medical indication criteria.",Yes,"FEP WES criteria commonly require prior chromosomal microarray for unexplained neurodevelopmental or congenital presentations; the patient had a nondiagnostic CMA, satisfying the documented prior-test requirement.",Yes,"Family history can be relevant for genetic testing eligibility; the record notes sudden unexplained death in an uncle <35, a family history detail supportive of a genetic evaluation for epilepsy-related syndromes.",Yes,"BCBS_FEP expects pre- and post-test genetic counseling/documentation for complex genomic testing. The patient has had multiple visits with a genetic counselor and arrangements for post-test genetics follow-up, meeting counseling requirements.",81415,The requested test is whole exome sequencing; CPT code 81415 corresponds to clinical exome (WES) sequencing and interpretation.,Yes,"Under BCBS_FEP WES criteria the patient meets age, medical indication (persistent suspected genetic epilepsy), required prior testing (nondiagnostic CMA), documented genetic counseling, and genetics involvement, therefore WES is covered.",1978,1696,3674
Case9773,baseline,without_policy,iter1,CMA,The clinical note explicitly states a chromosomal microarray (CMA) was ordered to assess for genomic copy number changes.,Not Specified,FEP/CMA coverage is indication-based (unexplained intellectual disability/developmental delay/autism or multiple congenital anomalies) and does not impose an age cutoff; no age-specific exclusion is specified.,Not Specified,FEP medical policy does not restrict CMA ordering to a specific specialty — any qualified ordering clinician may request testing; no specialty requirement is specified in the record.,Yes,Patient is a 2-year-old with severe intellectual disability; FEP policy lists unexplained intellectual disability/developmental delay as a covered clinical indication for CMA.,Not Specified,"FEP policy generally allows CMA as a first‑tier test for unexplained ID/DD and does not mandate prior genetic testing (e.g., karyotype) before CMA; no required prior tests are documented.",Not Specified,"Although the patient has a maternal aunt with a severe immunologic disorder, FEP CMA coverage is driven by the proband's clinical features (ID) rather than specific family-history requirements; family-history criteria are not specified as required.",Yes,"FEP policy expects documentation of genetic counseling for genomic testing; the family completed pre‑test genetic counseling and plans post‑test counseling, meeting counseling requirements.",81228,"CPT 81228 corresponds to chromosomal microarray analysis for genome‑wide copy number variants, which matches the ordered CMA.",Yes,"Under FEP policy the patient meets covered clinical indication (severe intellectual disability), pre‑test counseling is documented, no disqualifying age or prior‑test requirements apply, and the appropriate CPT is 81228 — therefore the CMA is covered.",1994,1617,3611
Case18257,baseline,without_policy,iter1,BRCA1/2,The clinical note explicitly states the patient is being evaluated for BRCA1/2 testing to assess hereditary breast and ovarian cancer risk.,Yes,"Cigna BRCA criteria include personal history of breast cancer diagnosed at age ≤50 as an indication; the patient had breast cancer diagnosed at age 50 or younger, so age-related eligibility is met.",Yes,"Cigna policies generally allow orders from licensed physicians or other qualified providers. The test was ordered by the patient's general practitioner (a physician), which satisfies ordering-provider requirements.",Yes,Cigna defines a personal history of breast cancer diagnosed ≤50 years as a covered medical indication for BRCA1/2 testing; the patient meets this specific clinical criterion.,Not Specified,"There are no Cigna prior-testing requirements (e.g., CMA or other tests) that must be completed before BRCA1/2 testing in this clinical scenario; the provided prior CMA result is informational but not a prerequisite.",No,"While family history can be relevant for BRCA testing, the only family detail provided (a sibling with short stature) is not a qualifying family history for hereditary breast/ovarian cancer per Cigna criteria.",No,"Cigna requires documentation of genetic counseling (pre-test and typically post-test) for BRCA testing; there is no documentation of prior genetic counseling for this patient, so counseling requirements are not met.",Not Specified,"The exact CPT codes for BRCA1/2 sequencing (e.g., single-gene BRCA1/BRCA2 codes) are not among the provided options, and the patient information does not specify test methodology that would map to the listed CPT codes.",No,"Although the patient meets medical and age criteria for BRCA1/2 testing under Cigna policy, the absence of documented genetic counseling (a Cigna coverage requirement) means coverage is not met as presented; counseling must be documented or provided per policy for approval.",1976,1975,3951
Case10075,baseline,without_policy,iter1,CMA,"The clinical note explicitly states 'consideration of chromosomal microarray (CMA) testing,' so the requested test is CMA.",Not Specified,BCBS_FEP CMA coverage criteria do not impose an age limit for CMA; the provided information does not identify any age-based exclusion or requirement for this infant.,Not Specified,"The documentation states the infant was seen by a developmental pediatrician and that pre-test counseling was completed by a genetic specialist, but payer-specific ordering-provider restrictions for CMA are not specified in the provided information.",No,"BCBS_FEP CMA coverage is limited to indications such as unexplained developmental delay/intellectual disability, autism spectrum disorder, or multiple congenital anomalies. The infant has meconium ileus and a sibling with an inborn error of metabolism (suggesting a single‑gene condition); these do not meet the specified CMA indications.",Not Specified,"Payer criteria typically do not require prior testing before initial CMA; however, here a prior CMA was already nondiagnostic. The policy-specified prior-test requirements (if any) are not provided in the record, so specific prior-test requirements cannot be confirmed.",No,"BCBS_FEP family-history criteria relevant to CMA would be a family history of a chromosomal abnormality. The documented family history is of an inborn error of metabolism in a sibling (a single‑gene disorder), which is not a family history that supports CMA eligibility.",Yes,"When required, BCBS_FEP expects documentation of informed genetic counseling for CMA. The record states pre-test counseling was completed with a genetic specialist and post-test follow-up arranged, satisfying counseling requirements.",Not Specified,"None of the provided CPT options unambiguously correspond to chromosomal microarray in the context of the listed choices, and the appropriate CMA CPT is not clearly represented among them.",No,"Applying BCBS_FEP coverage criteria: the infant does not meet defined medical indications for CMA (no unexplained developmental delay, intellectual disability, autism, or multiple congenital anomalies), and a prior CMA was nondiagnostic. Although counseling is documented, the clinical indication does not meet payer criteria, so CMA is not covered.",1991,2597,4588
